var title_f37_55_38768="Flurbiprofen: Patient drug information";
var content_f37_55_38768=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Flurbiprofen: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <div class=\"block note\" id=\"F12804640\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <p>",
"     Information for this drug is presented separately based upon the following methods of administration:",
"    </p>",
"   </div>",
"   <div class=\"sec_xr rmolist\" id=\"F12804641\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <ul xmlns=\"\">",
"     <li>",
"      <a class=\"drug drug_patient\" href=\"mobipreview.htm?38/3/38963?source=see_link\">",
"       Flurbiprofen (ophthalmic): Patient drug information",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_patient\" href=\"mobipreview.htm?35/35/36405?source=see_link\">",
"       Flurbiprofen (systemic): Patient drug information",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12491 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-122.72.80.101-1C61674EA5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_55_38768=[""].join("\n");
var outline_f37_55_38768=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   DRUG INFORMATION",
"   <br/>",
"   [by method of administration]",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?38/3/38963?source=related_link\">",
"      Flurbiprofen (ophthalmic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?35/35/36405?source=related_link\">",
"      Flurbiprofen (systemic): Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_55_38769="Exserohilum rostratum";
var content_f37_55_38769=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F86772&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F86772&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Exserohilum rostratum",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The genus is characterized by its conidia, which are ellipsoidal, distoseptate, and have a protruding and truncate hilum. Exserohilum spores have an inner cup-like structure, which is visible in the basal cell.",
"    <sup>",
"     [1]",
"    </sup>",
"    Colonies are grey to blackish-brown, suede-like to floccose in texture, and have an olivaceous black reverse. Conidia are straight, curved or slightly bent, ellipsoidal to fusiform, and are formed apically through a pore (poroconidia) on a sympodially elongating geniculate conidiophore. Conidia have a strongly protruding, truncate hilum and the septum above the hilum is usually thickened and dark. The end cells are often paler than the other cells and the walls are often finely roughened. Conidial germination is bipolar.",
"    <sup>",
"     [2]",
"    </sup>",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br>",
"      <ol>",
"       <li>",
"        American Air Testing, Inc. Available at:",
"        <a href=\"file://www.americanairtesting.com/\">",
"         file://www.americanairtesting.com/",
"        </a>",
"        &nbsp;(Accessed October 22, 2012).",
"       </li>",
"       <li>",
"        Mycology online. Exserohilum sp. The University of Adelaide 2012. Available at:",
"        <a href=\"file://www.mycology.adelaide.edu.au/Fungal_Descriptions/Hyphomycetes_(dematiaceous)/Exserohilum/\">",
"         file://www.mycology.adelaide.edu.au/Fungal_Descriptions/Hyphomycetes_(dematiaceous)/Exserohilum/",
"        </a>",
"        (Accessed October 22, 2012).",
"       </li>",
"      </ol>",
"      Reproduced from: United States Centers for Disease Control and Prevention. Multistate Meningitis Outbreak Investigation. Additional information available at:",
"      <a href=\"file://www.cdc.gov/HAI/outbreaks/meningitis.html\" style=\"FONT-STYLE: italic\" target=\"_blank\">",
"       file://www.cdc.gov/HAI/outbreaks/meningitis.html",
"      </a>",
"      (Accessed October 22, 2012).",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_55_38769=[""].join("\n");
var outline_f37_55_38769=null;
var title_f37_55_38770="Prostate cancer screening";
var content_f37_55_38770=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Prostate cancer screening (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?37/55/38770/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/55/38770/contributors\" id=\"au5554\">",
"       Richard M Hoffman, MD, MPH",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?37/55/38770/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/55/38770/contributors\" id=\"se323\">",
"       Robert H Fletcher, MD, MSc",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?37/55/38770/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/55/38770/contributors\" id=\"de6672\">",
"       David M Rind, MD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"mobipreview.htm?37/55/38770?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      PROSTATE CANCER SCREENING OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     Prostate cancer screening involves testing for prostate cancer in men who have no symptoms of the disease. This testing can find cancer at an early stage. However, medical experts disagree about whether prostate cancer screening is right for all men, and it is not clear if the benefits of screening outweigh the risks.",
"    </p>",
"    <p>",
"     This article is designed to review the advantages and disadvantages of prostate cancer screening. You should talk with your healthcare provider to decide what is best in your individual situation.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      WHAT IS PROSTATE CANCER?",
"     </span>",
"    </p>",
"    <p>",
"     Prostate cancer is a cancer of the prostate, a small gland in men that is located below the bladder and above the rectum (",
"     <a class=\"graphic graphic_figure graphicRef65675 \" href=\"mobipreview.htm?36/32/37382\">",
"      figure 1",
"     </a>",
"     ). The prostate produces fluid that helps carry sperm during ejaculation.",
"    </p>",
"    <p>",
"     Although many men are diagnosed with prostate cancer, most of them do not die from their cancer. Prostate cancer often grows so slowly that many men die of other causes before they even develop symptoms of prostate cancer.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H3\">",
"     <span class=\"h1\">",
"      PROSTATE CANCER RISK FACTORS",
"     </span>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H4\">",
"     <span class=\"h2\">",
"      Age",
"     </span>",
"     &nbsp;&mdash;&nbsp;All men are at risk for prostate cancer, but the risk greatly increases with older age. Prostate cancer is rarely found in men younger than 50 years old.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h2\">",
"      Ethnic background",
"     </span>",
"     &nbsp;&mdash;&nbsp;African American men develop prostate cancer more often than white and Hispanic men. African American men also are more likely to die of prostate cancer than white or Hispanic men.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h2\">",
"      Family medical history",
"     </span>",
"     &nbsp;&mdash;&nbsp;Men who have a first-degree relative (a father or brother) with prostate cancer are more likely to develop the disease. Men with female relatives with breast cancer related to the breast cancer gene (BRCA) may also be more likely to develop prostate cancer.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h2\">",
"      Diet",
"     </span>",
"     &nbsp;&mdash;&nbsp;A diet high in animal fat or low in vegetables may increase a man's risk of prostate cancer.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H8\">",
"     <span class=\"h1\">",
"      PROSTATE CANCER SCREENING TESTS",
"     </span>",
"    </p>",
"    <p>",
"     Prostate cancer screening involves blood test that measures prostate specific antigen (PSA).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9\">",
"     <span class=\"h2\">",
"      Prostate specific antigen (PSA)",
"     </span>",
"     &nbsp;&mdash;&nbsp;Prostate specific antigen (PSA) is a protein produced by the prostate. The PSA test measures the amount of PSA in a sample of blood. Although many men with prostate cancer have an elevated PSA concentration, a high level does not necessarily mean there is a cancer.",
"    </p>",
"    <p>",
"     The most common cause for an elevated PSA is benign prostatic hyperplasia (BPH), a noncancerous enlargement of the prostate. Other causes include prostate infection (prostatitis) and trauma (bicycle riding), and sexual activity. You should avoid ejaculating or riding a bike for at least 48 hours before having a PSA test. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?27/51/28467?source=see_link\">",
"      \"Patient information: Benign prostatic hyperplasia (BPH) (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10\">",
"     <span class=\"h2\">",
"      Rectal examination",
"     </span>",
"     &nbsp;&mdash;&nbsp;A rectal examination is often recommended, along with measurement of the PSA, to screen for prostate cancer. However, studies have not shown that rectal examination is an effective screening test for prostate cancer.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h2\">",
"      If the PSA test is positive",
"     </span>",
"     &nbsp;&mdash;&nbsp;A positive PSA test is not a reason to panic; noncancerous conditions are the most common causes for an abnormal test, particularly for PSA tests. On the other hand, a positive test should not be ignored.",
"    </p>",
"    <p>",
"     The first step in evaluating an elevated PSA is usually to repeat the test. In some cases, you may be treated for a prostate infection before repeating the test. Even if you are not treated for infection, you should avoid ejaculating and riding a bike for at least 48 hours before repeating the test. If the PSA remains elevated, a prostate biopsy is usually recommended.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12\">",
"     <span class=\"h3\">",
"      Prostate biopsy",
"     </span>",
"     &nbsp;&mdash;&nbsp;A prostate biopsy involves having a rectal ultrasound and use of a needle to obtain tissue samples from the prostate gland. The biopsy is usually performed in the office by a urologist (a doctor who specializes in treatment of urinary, bladder, and prostate issues). After the procedure, most men feel sore and you may see blood in the urine or semen.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H13\">",
"     <span class=\"h1\">",
"      PROS AND CONS OF PROSTATE CANCER SCREENING",
"     </span>",
"    </p>",
"    <p>",
"     There are a number of arguments for and against prostate cancer screening.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14\">",
"     <span class=\"h2\">",
"      Arguments for screening",
"     </span>",
"     &nbsp;&mdash;&nbsp;Experts in favor of prostate cancer screening cite the following arguments:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Results from a large European study of prostate cancer screening found that men who had PSA testing had a 20 percent lower chance of dying from prostate cancer after nine years, compared to men who did not have prostate cancer screening [",
"       <a class=\"abstract\" href=\"mobipreview.htm?37/55/38770/abstract/1\">",
"        1",
"       </a>",
"       ].",
"      </li>",
"      <li>",
"       A substantial number of men die from prostate cancer every year and many more suffer from the complications of advanced disease.",
"      </li>",
"      <li>",
"       For men with an aggressive prostate cancer, the best chance for curing it is by finding it at an early stage and then treating it with surgery or radiation. Studies have shown that men who have prostate cancer detected by PSA screening tend to have earlier-stage cancer than men who have a cancer detected by other means. (See",
"       <a class=\"medical medical_patient\" href=\"mobipreview.htm?41/41/42643?source=see_link\">",
"        \"Patient information: Treatment for advanced prostate cancer (Beyond the Basics)\"",
"       </a>",
"       and",
"       <a class=\"medical medical_patient\" href=\"mobipreview.htm?39/39/40565?source=see_link\">",
"        \"Patient information: Prostate cancer treatment; stage I to III cancer (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"      <li>",
"       The five-year survival for men who have prostate cancer confined to the prostate gland (early stage) is nearly 100 percent; this drops to 30 percent for men whose cancer has spread to other areas of the body. However, many early-stage cancers are not aggressive, and the five-year survival will be nearly 100 percent even without any treatment.",
"      </li>",
"      <li>",
"       The available screening tests are not perfect, but they are easy to perform and are fairly accurate.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H15\">",
"     <span class=\"h2\">",
"      Arguments against screening",
"     </span>",
"     &nbsp;&mdash;&nbsp;Other arguments have also been made against screening:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Even though the European study found a benefit of prostate cancer screening, only one man in every 1400 benefited from PSA testing after nine years [",
"       <a class=\"abstract\" href=\"mobipreview.htm?37/55/38770/abstract/1\">",
"        1",
"       </a>",
"       ]. Furthermore, 75 percent of men with an abnormal PSA who had a prostate biopsy did not have prostate cancer.",
"      </li>",
"      <li>",
"       A large American study did not find that prostate cancer screening reduced the chance of dying from prostate cancer [",
"       <a class=\"abstract\" href=\"mobipreview.htm?37/55/38770/abstract/2\">",
"        2",
"       </a>",
"       ].",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Many prostate cancers detected with screening are unlikely to cause death or disability. Thus, a number of men will be diagnosed with cancer and potentially suffer the side effects of cancer treatment for cancers that never would have been found without prostate cancer screening. In other words, even if screening finds a cancer early, it is not clear in all cases that the cancer must be treated.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H16\">",
"     <span class=\"h1\">",
"      IS PROSTATE CANCER SCREENING RIGHT FOR ME?",
"     </span>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H17\">",
"     <span class=\"h2\">",
"      Professional organizations",
"     </span>",
"     &nbsp;&mdash;&nbsp;Major medical associations and societies have conflicting recommendations regarding prostate cancer screening, making it difficult to decide if screening is right.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The United States Preventive Services Task Force [",
"       <a class=\"abstract\" href=\"mobipreview.htm?37/55/38770/abstract/3,4\">",
"        3,4",
"       </a>",
"       ] and many European cancer societies have",
"       <strong>",
"        not",
"       </strong>",
"       endorsed routine PSA screening to detect prostate cancer.",
"      </li>",
"      <li>",
"       The American Cancer Society [",
"       <a class=\"abstract\" href=\"mobipreview.htm?37/55/38770/abstract/5\">",
"        5",
"       </a>",
"       ] and American Urological Association [",
"       <a class=\"abstract\" href=\"mobipreview.htm?37/55/38770/abstract/6\">",
"        6",
"       </a>",
"       ]&nbsp;recommend that men consider having prostate cancer screening after discussing the risks and benefits with a healthcare provider.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Most expert groups recommend that you have an open discussion with your clinician about the risks and benefits of treatment.",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Consider your own prostate cancer risk factors",
"      </li>",
"      <li>",
"       Know the potential benefits and harms of screening, diagnosis, and treatment",
"      </li>",
"      <li>",
"       Talk to your clinician about concerns or questions",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H18\">",
"     <span class=\"h2\">",
"      For men who choose screening",
"     </span>",
"     &nbsp;&mdash;&nbsp;If you choose to have prostate cancer screening, you should begin at age 50, although some guidelines suggest beginning at age 40. Men with risk factors for prostate cancer (such as black men or a man with a father or brother who had prostate cancer) may want to begin screening at age 40 to 45.",
"    </p>",
"    <p>",
"     Once screening begins, it should occur every two to four years and should include a PSA blood test. Some guidelines recommend yearly testing that also includes a rectal examination. (See",
"     <a class=\"local\" href=\"#H8\">",
"      'Prostate cancer screening tests'",
"     </a>",
"     above.)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H19\">",
"     <span class=\"h2\">",
"      Screening not recommended",
"     </span>",
"     &nbsp;&mdash;&nbsp;Screening is not recommended for men who are 75 years and older or for men who have serious health problems. In these situations, the benefits of screening are not worth the potential harms.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H20\">",
"     <span class=\"h1\">",
"      PROSTATE CANCER PREVENTION",
"     </span>",
"    </p>",
"    <p>",
"     All men who are African American, older than age 50, or have a positive family history of prostate cancer are at an increased risk of developing prostate cancer. These men may consider a strategy to reduce the chances of developing prostate cancer, although it is important to balance the potential risks and benefits of these preventive treatments.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H21\">",
"     <span class=\"h2\">",
"      Supplements",
"     </span>",
"     &nbsp;&mdash;&nbsp;Two dietary supplements, vitamin E and selenium, were previously thought to reduce the risk of prostate cancer. However, studies have not proven any benefit of these supplements and they are not recommended.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H22\">",
"     <span class=\"h2\">",
"      Medications",
"     </span>",
"     &nbsp;&mdash;&nbsp;In men at risk for prostate cancer, finasteride (Proscar&reg;) has been shown to reduce the risk of developing prostate cancer by about 25 percent [",
"     <a class=\"abstract\" href=\"mobipreview.htm?37/55/38770/abstract/7\">",
"      7",
"     </a>",
"     ]. Similar reductions in prostate cancer also have been seen with dutasteride (Avodart&reg;) [",
"     <a class=\"abstract\" href=\"mobipreview.htm?37/55/38770/abstract/8\">",
"      8",
"     </a>",
"     ]. Whether or not to use these medications, which block the effects of testosterone on the prostate, to prevent prostate cancer is a complex issue that must consider the following:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The benefits of finasteride and dutasteride (decreased incidence of prostate cancer, decreased symptoms and complications of benign prostatic hypertrophy)",
"      </li>",
"      <li>",
"       The known and potential side effects of such treatment (reduced sexual function, apparent increase in aggressive cancers [",
"       <a class=\"abstract\" href=\"mobipreview.htm?37/55/38770/abstract/9\">",
"        9",
"       </a>",
"       ]) (See",
"       <a class=\"medical medical_patient\" href=\"mobipreview.htm?27/51/28467?source=see_link\">",
"        \"Patient information: Benign prostatic hyperplasia (BPH) (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Men who take finasteride or dutasteride often have a prostate-specific antigen (PSA) level that is decreased by about 50 percent. This is important to consider when interpreting the results of a prostate specific antigen (PSA).",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H23\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H231\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H292592345\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?31/27/32176?source=see_link\">",
"      Patient information: Prostate cancer screening (PSA tests) (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?2/3/2099?source=see_link\">",
"      Patient information: Prostate cancer (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?9/63/10227?source=see_link\">",
"      Patient information: Cancer screening (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?3/15/3315?source=see_link\">",
"      Patient information: Choosing treatment for low-risk localized prostate cancer (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H292592401\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?41/41/42643?source=see_link\">",
"      Patient information: Treatment for advanced prostate cancer (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?39/39/40565?source=see_link\">",
"      Patient information: Prostate cancer treatment; stage I to III cancer (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?27/51/28467?source=see_link\">",
"      Patient information: Benign prostatic hyperplasia (BPH) (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H25\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/2/41001?source=see_link\">",
"      Measurement of prostate specific antigen",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/8/42122?source=see_link\">",
"      Screening for prostate cancer",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Cancer Institute",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp; 1-800-4-CANCER",
"     <br/>",
"     &nbsp; &nbsp; &nbsp; (",
"     <a class=\"external\" href=\"file://www.cancer.gov/cancertopics/screening/prostate\">",
"      www.cancer.gov/cancertopics/screening/prostate",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       People Living With Cancer: The official patient information",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;website of the American Society of Clinical Oncology",
"     <br/>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.cancer.net/portal/site/patient\">",
"      www.cancer.net/portal/site/patient",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Comprehensive Cancer Network",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nccn.com/\">",
"      www.nccn.com",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American Cancer Society",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp; 1-800-ACS-2345",
"     <br/>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.cancer.org/\">",
"      www.cancer.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/healthtopics.html\">",
"      www.nlm.nih.gov/medlineplus/healthtopics.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       US TOO! Prostate Cancer Education and Support",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.ustoo.com/Early_Detection.asp\">",
"      www.ustoo.com/Early_Detection.asp",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"mobipreview.htm?37/55/38770/abstract/1,3-9\">",
"      1,3-9",
"     </a>",
"     ] &nbsp;",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 16, 2011.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"mobipreview.htm?37/55/38770?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/55/38770/abstract/1\">",
"      Schr&ouml;der FH, Hugosson J, Roobol MJ, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009; 360:1320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/55/38770/abstract/2\">",
"      Andriole GL, Crawford ED, Grubb RL 3rd, et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009; 360:1310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/55/38770/abstract/3\">",
"      U.S. Preventive Services Task Force. Screening for prostate cancer: recommendation and rationale. Ann Intern Med 2002; 137:915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/55/38770/abstract/4\">",
"      Lin K, Lipsitz R, Miller T, et al. Benefits and harms of prostate-specific antigen screening for prostate cancer: an evidence update for the U.S. Preventive Services Task Force. Ann Intern Med 2008; 149:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/55/38770/abstract/5\">",
"      Smith RA, von Eschenbach AC, Wender R, et al. American Cancer Society guidelines for the early detection of cancer: update of early detection guidelines for prostate, colorectal, and endometrial cancers. Also: update 2001--testing for early lung cancer detection. CA Cancer J Clin 2001; 51:38.",
"     </a>",
"    </li>",
"    <li>",
"     Prostate-specific antigen best practice statement: 2009 update. American Urological Association. Availabale online at: www.auanet.org/content/guidelines-and-quality-care/clinical-guidelines/main-report/psa09.pdf (Accessed June 11, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/55/38770/abstract/7\">",
"      Kramer BS, Hagerty KL, Justman S, et al. Use of 5-alpha-reductase inhibitors for prostate cancer chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice Guideline. J Clin Oncol 2009; 27:1502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/55/38770/abstract/8\">",
"      Andriole GL, Bostwick DG, Brawley OW, et al. Effect of dutasteride on the risk of prostate cancer. N Engl J Med 2010; 362:1192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/55/38770/abstract/9\">",
"      Theoret MR, Ning YM, Zhang JJ, et al. The risks and benefits of 5&alpha;-reductase inhibitors for prostate-cancer prevention. N Engl J Med 2011; 365:97.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f37_55_38770=[""].join("\n");
var outline_f37_55_38770=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           PROSTATE CANCER SCREENING OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           WHAT IS PROSTATE CANCER?",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H3\">",
"           PROSTATE CANCER RISK FACTORS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H8\">",
"           PROSTATE CANCER SCREENING TESTS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H13\">",
"           PROS AND CONS OF PROSTATE CANCER SCREENING",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H16\">",
"           IS PROSTATE CANCER SCREENING RIGHT FOR ME?",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H20\">",
"           PROSTATE CANCER PREVENTION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H23\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          FIGURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?36/32/37382\" title=\"figure 1\">",
"           Prostate anatomy PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f37_55_38771="Ecthyma gangrenosum purpura";
var content_f37_55_38771=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F53544&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F53544&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Ecthyma gangrenosum",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Retiform purpuric lesions in a patient with ecthyma gangrenosum.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_55_38771=[""].join("\n");
var outline_f37_55_38771=null;
var title_f37_55_38772="Cushings disease MRI I";
var content_f37_55_38772=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F75003&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F75003&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 552px\">",
"   <div class=\"ttl\">",
"    Magnetic resonance imaging in Cushing's disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 532px; height: 271px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Thirty-seven-year-old woman with Cushing's disease caused by a 9 x 11 x 14 mm corticotroph macroadenoma. Left panel: Coronal section of unenhanced MR image of the sella turcica. The macroadenoma appears as an area of decreased signal intensity impinging upon the optic chasm above and the sphenoid sinus below (arrows). Right panel: Coronal gadolinium-enhanced MR image of the sella turcica. The microadenoma appears as an area of enhanced signal intensity with some areas of nonhomogeneity.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reprinted with permission from Williams Textbook of Endocrinology, 8th ed, Foster, DW, Wilson, JD (Eds), WB Saunders, Philadelphia, 1996.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_55_38772=[""].join("\n");
var outline_f37_55_38772=null;
var title_f37_55_38773="Ziconotide: Drug information";
var content_f37_55_38773=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Ziconotide: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?18/55/19316?source=see_link\">",
"    see \"Ziconotide: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708845\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F235295\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Prialt&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F235310\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Analgesic, Nonopioid;",
"     </li>",
"     <li>",
"      Calcium Channel Blocker, N-Type",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F235297\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Chronic pain:",
"     </b>",
"     I.T.: Initial dose: &le;2.4 mcg/day (0.1 mcg/hour)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dose may be titrated by &le;2.4 mcg/day (0.1 mcg/hour) at intervals &le;2-3 times/week to a maximum dose of 19.2 mcg/day (0.8 mcg/hour) by day 21; average dose at day 21: 6.9 mcg/day (0.29 mcg/hour). A faster titration should be used only if the urgent need for analgesia outweighs the possible risk to patient safety.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F235298\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing. Use with caution.",
"    </p>",
"   </div>",
"   <div class=\"block dot drugH1Div\" id=\"F235311\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adjustment for Toxicity",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cognitive impairment: Reduce dose or discontinue. Effects are generally reversible within 3-15 days of discontinuation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Reduced level of consciousness: Discontinue until event resolves.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     CK elevation with neuromuscular symptoms: Consider dose reduction or discontinuation.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F235276\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infusion, intrathecal, as acetate [preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Prialt&reg;: 25 mcg/mL (20 mL); 100 mcg/mL (1 mL, 5 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F235265\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F235279\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Not for I.V. administration.",
"     </b>",
"     <b>",
"      For I.T. administration only",
"     </b>",
"     using Medtronic SynchroMed&reg; EL, SynchroMed&reg; II Infusion System, or CADD-Micro&reg; ambulatory infusion pump.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Medtronic SynchroMed&reg; EL or SynchroMed&reg; II Infusion Systems:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Naive pump priming (first time use with ziconotide): Use 2 mL of undiluted ziconotide 25 mcg/mL solution to rinse the internal surfaces of the pump; repeat twice for a total of 3 rinses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Initial pump fill: Use only undiluted 25 mcg/mL solution and fill pump after priming. Following the initial fill only, adsorption on internal device surfaces will occur, requiring the use of the undiluted solution and refill within 14 days.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pump refills: Contents should be emptied prior to refill. Subsequent pump refills should occur at least every 40 days if using diluted solution or at least every 84 days if using undiluted solution.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     CADD-Micro&reg; ambulatory infusion pump: Refer to manufacturer's manual for initial fill and refill instructions",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F235278\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Management of severe chronic pain in patients requiring intrathecal (I.T.) therapy and who are intolerant or refractory to other therapies",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F5174564\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F235308\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Dizziness (46%), confusion (15% to 33%), memory impairment (7% to 22%), somnolence (17%), ataxia (14%), speech disorder (14%), headache (13%), aphasia (12%), hallucination (12%; including auditory and visual)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea (40%), diarrhea (18%), vomiting (16%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Creatine kinase increased (40%; &ge;3 times ULN: 11%), weakness (18%), gait disturbances (14%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Blurred vision (12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     2% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Hypotension, orthostatic hypotension, peripheral edema",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Abnormal thinking (8%), amnesia (8%), anxiety (8%), vertigo (7%), insomnia (6%), fever (5%), paranoid reaction (3%), delirium (2%), hostility (2%), stupor (2%), agitation, attention disturbance, balance impaired, burning sensation, coordination abnormal, depression, disorientation, fatigue, fever, hypoesthesia, irritability, lethargy, mental impairment, mood disorder, nervousness, pain, sedation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Pruritus (7%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Anorexia (6%), taste perversion (5%), abdominal pain, appetite decreased, constipation, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Urinary retention (9%), dysuria, urinary hesitance",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Dysarthria (7%), paresthesia (7%), rigors (7%), tremor (7%), muscle spasm (6%), limb pain (5%), areflexia, muscle cramp, muscle weakness, myalgia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Nystagmus (8%), diplopia, visual disturbance",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Sinusitis (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Diaphoresis (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;2% (Limited to important or life-threatening): Acute renal failure, aspiration pneumonia (&lt;1%), atrial fibrillation, cerebral vascular accident, ECG abnormalities, incoherence, loss of consciousness, mania, meningitis, myoclonus, psychosis (1%), psychotic disorder, respiratory distress, rhabdomyolysis, seizure (clonic and grand mal), sepsis, suicidal ideation, suicide attempt (&lt;1%)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F235282\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to ziconotide or any component of the formulation; history of psychosis; I.V. administration",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.T. administration is contraindicated in patients with infection at the injection site, uncontrolled bleeding, or spinal canal obstruction that impairs CSF circulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F235267\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS toxicity:",
"     <b>",
"      [U.S Boxed Warning]: Severe psychiatric symptoms and neurological impairment have been reported;",
"     </b>",
"     interrupt or discontinue therapy if cognitive impairment, hallucinations, mood changes, or changes in consciousness occur. May cause or worsen depression and/or risk of suicide. Cognitive impairment may appear gradually during treatment and is generally reversible after discontinuation (may take up to 2 weeks for cognitive effects to reverse). May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elevated serum creatine kinase: With use, elevated serum creatine kinase can occur; particularly during the first 2 months of therapy. Consider dose reduction or discontinuing if combined with new neuromuscular symptoms (myalgias, myasthenia, muscle cramps, weakness) or reduction in physical activity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Meningitis: May occur with use of I.T. pumps; monitor for signs of meningitis; treatment of meningitis may require removal of system and discontinuation of intrathecal therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Safety and efficacy have not been established in patients with hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Safety and efficacy have not been established in patients with renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS depressants: May have additive effects with CNS-depressant medications.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Opiates: May have additive CNS effects with opiates and may potentiate opioid-induced decreased GI motility; does not interact with opioid receptors or potentiate opiate-induced respiratory depression.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use with caution in the elderly; may experience a higher incidence of confusion.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Safety and efficacy have not been established in children.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Withdrawal: Will not prevent or relieve symptoms associated with opiate withdrawal; unlike opioids, ziconotide therapy can be interrupted abruptly or discontinued without evidence of withdrawal.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300234\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F235271\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of CNS depressants used in combination with buprenorphine.  Consider avoiding other CNS depressants in patients thought to be at high risk of buprenorphine overuse or self-injection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F5028462\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ethanol: May increase CNS depression; monitor for increased effects with coadministration. Caution patients about effects.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F235273\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F235284\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects were not observed in animal studies, but increased postimplantation pup loss was reported. Maternal toxicity was also noted. There are no adequate and well-controlled studies in pregnant women.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F235300\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F235285\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The manufacturer recommends discontinuing breast-feeding or discontinuing ziconotide.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16324111\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Prialt Intrathecal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mcg/mL (1 mL): $766.94",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 mcg/20 mL (20 mL): $3834.70",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 mcg/5 mL (5 mL): $3834.70",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F235274\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Monitor for psychiatric or neurological impairment; signs and symptoms of meningitis or other infection; serum CPK (every other week for first month then monthly); pain relief",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F5539956\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Prialt (AT, BE, BG, CH, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HN, IE, IT, MT, NL, NO, PL, PT, RU, SE, SK, TR)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F235266\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ziconotide selectively binds to N-type voltage-sensitive calcium channels located on the nociceptive afferent nerves of the dorsal horn in the spinal cord. This binding is thought to block N-type calcium channels, leading to a blockade of excitatory neurotransmitter release and reducing sensitivity to painful stimuli.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F235281\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: I.T.: V",
"     <sub>",
"      d",
"     </sub>",
"     : ~140 mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: ~50%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Metabolized via endopeptidases and exopeptidases present on multiple organs including kidney, liver, lung; degraded to peptide fragments and free amino acids",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: I.V.: 1-1.6 hours (plasma); I.T.: 2.9-6.5 hours (CSF)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: I.V.: Urine (&lt;1%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Jain KK, &ldquo;An Evaluation of Intrathecal Ziconotide for the Treatment of Chronic Pain,&rdquo;",
"      <i>",
"       Expert Opin Investig Drugs",
"      </i>",
"      , 2000, 9(10):2403-10.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/55/38773/abstract-text/11060815/pubmed\" id=\"11060815\" target=\"_blank\">",
"        11060815",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Miljanich GP, &ldquo;Ziconotide: Neuronal Calcium Channel Blocker for Treating Severe Chronic Pain,&rdquo;",
"      <i>",
"       Curr Med Chem",
"      </i>",
"      , 2004, 11(23):3029-40.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/55/38773/abstract-text/15578997/pubmed\" id=\"15578997\" target=\"_blank\">",
"        15578997",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Staats PS, Yearwood T, Charapata SG, et al, &ldquo;Intrathecal Ziconotide in the Treatment of Refractory Pain in Patients With Cancer or AIDS: A Randomized Controlled Trial,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2004, 291(1):63-70.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/55/38773/abstract-text/14709577/pubmed\" id=\"14709577\" target=\"_blank\">",
"        14709577",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wermeling D, Drass M, Ellis D, et al, &ldquo;Pharmacokinetics and Pharmacodynamics of Intrathecal Ziconotide in Chronic Pain Patients,&rdquo;",
"      <i>",
"       J Clin Pharmacol",
"      </i>",
"      , 2003, 43(6):624-36.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/55/38773/abstract-text/12817525/pubmed\" id=\"12817525\" target=\"_blank\">",
"        12817525",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10333 Version 40.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-122.72.76.133-287B6DBA01-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_55_38773=[""].join("\n");
var outline_f37_55_38773=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708845\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235295\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235310\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235297\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235298\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235311\">",
"      Dosing: Adjustment for Toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235276\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235265\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235279\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235278\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5174564\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235308\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235282\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235267\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300234\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235271\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5028462\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235273\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235284\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235300\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235285\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16324111\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235274\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5539956\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235266\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235281\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10333\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10333|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?18/55/19316?source=related_link\">",
"      Ziconotide: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_55_38774="Intermediate case 6";
var content_f37_55_38774=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F76280&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F76280&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1054px;\">",
"  <div class=\"figure\" style=\"width: 484px\">",
"   <div class=\"ttl\">",
"    Intermediate case 6",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 464px; height: 101px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal rhythm strip",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 165px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Normal rhythm strip in lead II. The PR interval is 0.15 sec and the QRS duration is 0.08 sec. Both the P and T waves are upright.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Morton F Arnsdorf, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_55_38774=[""].join("\n");
var outline_f37_55_38774=null;
var title_f37_55_38775="Pretreatment agents for rapid sequence intubation in adults";
var content_f37_55_38775=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pretreatment agents for rapid sequence intubation in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/55/38775/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/55/38775/contributors\">",
"     David Caro, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/55/38775/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/55/38775/contributors\">",
"     Ron M Walls, MD, FRCPC, FAAEM",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/55/38775/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/55/38775/contributors\">",
"     Jonathan Grayzel, MD, FAAEM",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?37/55/38775/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 7, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first task of any clinician managing an acutely unstable patient is to secure the airway. Emergency clinicians often use rapid sequence intubation (RSI) to accomplish this task.",
"   </p>",
"   <p>",
"    RSI is the most common method used in emergency airway management for intubations not anticipated to be difficult. RSI involves the use of a sedative and a neuromuscular blocking agent to render a patient rapidly unconscious and flaccid for emergent endotracheal intubation and to minimize the risk of aspiration.",
"   </p>",
"   <p>",
"    Manipulation of the airway during laryngoscopy and endotracheal intubation causes physiologic responses that may be harmful to patients with specific medical conditions. Pretreatment agents may be incorporated into RSI protocols to blunt such physiologic responses and protect patients from their potentially harmful effects.",
"   </p>",
"   <p>",
"    The use of pretreatment medications for RSI will be reviewed here. The performance of RSI, including the use of induction and neuromuscular blocking agents, and other aspects of emergency airway management are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/55/1912?source=see_link\">",
"     \"Rapid sequence intubation in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/29/24026?source=see_link\">",
"     \"Rapid sequence intubation (RSI) in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/30/11754?source=see_link\">",
"     \"Sedation or induction agents for rapid sequence intubation in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/35/31288?source=see_link\">",
"     \"Neuromuscular blocking agents (NMBA) for rapid sequence intubation in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PHYSIOLOGIC RESPONSES TO LARYNGOSCOPY AND INTUBATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pharynx, larynx, and carina of the trachea are highly innervated with sympathetic and parasympathetic nerves. The innervation of the upper and lower airways is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/60/10186?source=see_link\">",
"     \"Neuronal control of the airways\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Performing laryngoscopy and placing an endotracheal tube stimulate these nerves and cause reflexive actions to protect the airway, such as gagging and coughing. Other reflexive responses to airway manipulation include parasympathetic stimulation in infants that can cause profound bradycardia, sympathetic stimulation in adults that can cause significant increases in heart rate, blood pressure, and intracranial pressure, and parasympathetically mediated bronchospasm.",
"   </p>",
"   <p>",
"    Studies demonstrate that laryngoscopy causes a mean increase in systolic blood pressure of approximately 20 mmHg [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/55/38775/abstract/1-5\">",
"     1-5",
"    </a>",
"    ]. Studies looking directly at the effect of laryngoscopy upon intracranial pressure are lacking, but endotracheal suctioning causes a minimum of a 5 mmHg elevation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/55/38775/abstract/6,7\">",
"     6,7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PRETREATMENT MEDICATIONS AND THEIR INDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pretreatment medications have the potential for both benefit and risk. Emergent airway management involves a series of steps that must be performed in a specific sequence and at the correct times. Thus, any steps and medications that have not been shown to provide a clear benefit are often best omitted, thereby reducing clinician anxiety and the risk of cognitive error. This is particularly true in pediatric resuscitations.",
"   </p>",
"   <p>",
"    To be effective, pretreatment agents generally must be administered at least three minutes prior to laryngoscopy. However, in highly emergent cases, it may not be worthwhile to delay intubation in order to allow pretreatment agents to take effect. In such cases, the pretreatment agents may be given less than three minutes before planned laryngoscopy, or omitted entirely.",
"   </p>",
"   <p>",
"    For these reasons, pretreatment should be viewed as a supplementary step in rapid sequence intubation (RSI). Proper sedation and neuromuscular blockade take priority when considering the medications for RSI. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/30/11754?source=see_link\">",
"     \"Sedation or induction agents for rapid sequence intubation in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/35/31288?source=see_link\">",
"     \"Neuromuscular blocking agents (NMBA) for rapid sequence intubation in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pretreatment medications are used to avert the potentially harmful consequences of the physiologic responses to airway manipulation during laryngoscopy and endotracheal intubation described above. Such responses can be particularly harmful in young children (ie, bradycardia from vagal stimulation) and in patients with high airway resistance (eg, severe asthma), elevated intracranial pressure (eg, intracranial hemorrhage), or cardiovascular conditions exacerbated by sudden increases in heart rate or blood pressure (eg, acute coronary syndrome, aortic dissection).",
"   </p>",
"   <p>",
"    The mnemonic \"ABC\" has been proposed to help practitioners recall the conditions under which these medications may be used: high airway resistance (\"Asthma\"), high intracranial pressure and pediatric intubations (\"Brains and Babies\"), and specific cardiovascular conditions (\"Cardiovascular\") [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/55/38775/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Potential pretreatment agents include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?11/23/11640?source=see_link\">",
"       Atropine",
"      </a>",
"      to blunt vagal stimulation in infants less than one year of age.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/34/35360?source=see_link\">",
"       Lidocaine",
"      </a>",
"      to reduce bronchospasm, and blunt increases in intracranial pressure.",
"     </li>",
"     <li>",
"      Ultrashort-acting opioid (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/52/38730?source=see_link\">",
"       fentanyl",
"      </a>",
"      ) to decrease the cardiovascular effects of sympathetic nervous system stimulation, which in turn, blunt increases in intracranial pressure due to loss of autoregulation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Each of these agents is discussed below.",
"   </p>",
"   <p>",
"    In the past, a small (ie, defasciculating) dose of a nondepolarizing neuromuscular blocking agent was frequently given as pretreatment when",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/46/33510?source=see_link\">",
"     succinylcholine",
"    </a>",
"    was used for RSI. Such pretreatment was thought to blunt the potential rise in intracranial pressure caused by the fasciculations that accompany succinylcholine administration. However, this approach is not supported by high quality evidence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/55/38775/abstract/9\">",
"     9",
"    </a>",
"    ]. In addition, evidence does not support the use of defasciculating pretreatment in patients with elevated intraocular pressure. Defasciculation for patients with elevated ICP or intraocular pressure is no longer recommended. Side effects associated with succinylcholine are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/35/31288?source=see_link\">",
"     \"Neuromuscular blocking agents (NMBA) for rapid sequence intubation in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A number of other medications have been proposed for use as pretreatment agents, including beta blockers and calcium channel blockers. However, there is insufficient evidence to support the use of calcium channel blockers, and beta blockade usually is not desirable in patients requiring emergent intubation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Atropine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/23/11640?source=see_link\">",
"     Atropine",
"    </a>",
"    is used in children, particularly young infants, who may have a pronounced vagal response to laryngoscopy. Atropine may be used to blunt this response. The use of atropine for RSI in children is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/29/24026?source=see_link\">",
"     \"Rapid sequence intubation (RSI) in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In adults,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/23/11640?source=see_link\">",
"     atropine",
"    </a>",
"    had been used primarily to blunt muscarinic stimulation and potential bradycardia in patients receiving a second dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/46/33510?source=see_link\">",
"     succinylcholine",
"    </a>",
"    during RSI. This approach was based upon the results of a few small observational studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/55/38775/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. Evidence from subsequent randomized trials assessing the efficacy of atropine in this setting is unconvincing, and some studies report possible harm from atropine. The following observations illustrate the range of findings from these trials:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One trial found no episodes of significant bradycardia or other arrhythmia among 20 patients pretreated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?11/23/11640?source=see_link\">",
"       atropine",
"      </a>",
"      who then received a second dose of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/46/33510?source=see_link\">",
"       succinylcholine",
"      </a>",
"      &nbsp;[",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/55/38775/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In two randomized trials, a small number of subjects became bradycardic after a second dose of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/46/33510?source=see_link\">",
"       succinylcholine",
"      </a>",
"      despite pretreatment with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?11/23/11640?source=see_link\">",
"       atropine",
"      </a>",
"      &nbsp;[",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/55/38775/abstract/13,14\">",
"       13,14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In four other randomized trials,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?11/23/11640?source=see_link\">",
"       atropine",
"      </a>",
"      pretreatment was associated with no bradycardic events but multiple episodes of tachyarrhythmias, including a small number of cases of ventricular tachycardia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/55/38775/abstract/15-18\">",
"       15-18",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Based upon these observations, we suggest that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/23/11640?source=see_link\">",
"     atropine",
"    </a>",
"    NOT be used routinely prior to a second dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/46/33510?source=see_link\">",
"     succinylcholine",
"    </a>",
"    . Atropine should be readily available as a rescue medication if bradycardia occurs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Lidocaine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/34/35360?source=see_link\">",
"     Lidocaine",
"    </a>",
"    may attenuate the rise in airway resistance and intracranial pressure that occur during laryngoscopy and intubation. We suggest the use of lidocaine as a pretreatment agent for patients undergoing rapid sequence intubation (RSI) who have increased airway resistance (eg, active asthma exacerbation) or increased intracranial pressure (eg, intracranial hemorrhage). There is insufficient evidence to determine whether lidocaine reduces reactive bronchospasm in patients who have received adequate doses of a beta-2 agonist (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/61/16344?source=see_link\">",
"     albuterol",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    dose is 1.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    intravenously (IV), given two to three minutes before intubation. Broad clinical experience suggests that lidocaine pretreatment is safe when given in this dose. Its onset of action is 45 to 90 seconds, and its effects last for 20 minutes. Lidocaine is metabolized by the liver and excreted in the urine. If there is not sufficient time to allow for lidocaine administration three minutes before intubation, lidocaine can be given in a shorter interval, immediately after intubation, or not at all.",
"   </p>",
"   <p>",
"    Absolute contraindications to pretreatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    include a known lidocaine allergy and high grade heart block (Mobitz type II or third degree) in a patient without a functioning pacemaker. Lidocaine can cause cardiac arrest in the setting of a high grade heart block.",
"   </p>",
"   <p>",
"    Multiple randomized trials have demonstrated that 1.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    IV of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    can suppress cough reflexes when administered one to three minutes prior to intubation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/55/38775/abstract/19-27\">",
"     19-27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Evidence that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    reduces bronchospasm is less clear. Studies in healthy volunteers suggest that pretreatment with lidocaine mitigates bronchial reactivity induced with inhaled histamine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/55/38775/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. However, in a small randomized trial of asthmatic patients undergoing general anaesthesia, pretreatment with lidocaine did not prevent an increase in airway resistance during intubation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/55/38775/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is no high quality evidence that directly addresses whether pretreatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    effectively reduces the rise in intracranial pressure (ICP) caused by laryngoscopy and endotracheal intubation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/55/38775/abstract/31-33\">",
"     31-33",
"    </a>",
"    ]. What little evidence exists consists of small trials that have reached contradictory conclusions. Two small randomized trials found that lidocaine minimized the rise in ICP in patients undergoing neurosurgical procedures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/55/38775/abstract/34\">",
"     34",
"    </a>",
"    ] or endotracheal suctioning [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/55/38775/abstract/35\">",
"     35",
"    </a>",
"    ]. In contrast, three other randomized trials found no benefit from pretreatment with lidocaine in blunting ICP rise during intubation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/55/38775/abstract/36,37\">",
"     36,37",
"    </a>",
"    ] or endotracheal suctioning [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/55/38775/abstract/38\">",
"     38",
"    </a>",
"    ]. The largest of these trials involved 124 patients undergoing general anaesthesia and endotracheal intubation in preparation for neurosurgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/55/38775/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite the conflicting evidence, we believe",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    is a reasonable pretreatment agent given its relative safety and the potential benefit of blunting ICP elevations in patients at risk for secondary brain injury.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Ultrashort-acting opioid",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ultrashort-acting opioids blunt the sympathetic response to laryngoscopy. We suggest the use of ultrashort-acting opioids (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/52/38730?source=see_link\">",
"     fentanyl",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/9/3223?source=see_link\">",
"     alfentanil",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/47/15094?source=see_link\">",
"     sufentanil",
"    </a>",
"    ) as pretreatment agents for patients undergoing rapid sequence intubation (RSI) who have elevated intracranial pressure (ICP) or cardiovascular disease that may be exacerbated by sudden elevations in blood pressure.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/52/38730?source=see_link\">",
"     Fentanyl",
"    </a>",
"    is used most often in the emergency setting. The dose is 3",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    IV given over 30 to 60 seconds to minimize the likelihood of respiratory depression. It is given approximately three minutes before the induction medication is administered and should be the last pretreatment drug given.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/52/38730?source=see_link\">",
"     Fentanyl",
"    </a>",
"    is an opioid receptor agonist. Its effects begin within two to three minutes of administration; its duration of action is 30 to 60 minutes. Fentanyl can cause respiratory depression and hypotension. In patients with tenuous hemodynamic status, fentanyl should be avoided or given in lower doses (1",
"    <span class=\"nowrap\">",
"     mcg/kg).",
"    </span>",
"   </p>",
"   <p>",
"    Several randomized controlled trials have found",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/52/38730?source=see_link\">",
"     fentanyl",
"    </a>",
"    to be effective at attenuating rises in blood pressure and heart rate during RSI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/55/38775/abstract/39-41\">",
"     39-41",
"    </a>",
"    ]. No data exist regarding the effects of fentanyl on the ICP of patients with acute head injuries undergoing RSI. In one small randomized trial of intubated patients with a severe head injury, the combination of a neuromuscular blocking agent and opioid was more effective in reducing ICP elevation caused by endotracheal suctioning than either drug alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/55/38775/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In rare instances",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/52/38730?source=see_link\">",
"     fentanyl",
"    </a>",
"    causes a \"rigid chest\" syndrome, in which the patient becomes apneic and cannot be ventilated or oxygenated with a bag mask. Rigidity is abolished by the administration of paralyzing doses of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/46/33510?source=see_link\">",
"     succinylcholine",
"    </a>",
"    (SCh) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/55/38775/abstract/43\">",
"     43",
"    </a>",
"    ]. Reported cases generally involve a single, rapidly administered, large dose of fentanyl, many-fold higher than the doses used for emergent RSI.",
"   </p>",
"   <p>",
"    Muscle wall rigidity is an idiosyncratic response to opioids and is probably related to the dose and speed of opioid administration. In an observational study of 380 patients undergoing cardiac surgery, high dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/52/38730?source=see_link\">",
"     fentanyl",
"    </a>",
"    (100",
"    <span class=\"nowrap\">",
"     mcg/kg,",
"    </span>",
"    or approximately 30 times the dose used in rapid sequence intubation) caused approximately eight percent of patients to develop extreme thoracic and abdominal rigidity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/55/38775/abstract/44\">",
"     44",
"    </a>",
"    ]. There is a single case report of rigidity in a patient who received fentanyl at a dose of 2",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    while taking",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/45/22233?source=see_link\">",
"     venlafaxine",
"    </a>",
"    , a serotonin and norepinephrine reuptake inhibitor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/55/38775/abstract/45\">",
"     45",
"    </a>",
"    ]. Fentanyl has been widely used for procedural sedation in doses similar to those used for RSI, and reports of muscle rigidity are virtually absent, even from large series [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/55/38775/abstract/46,47\">",
"     46,47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     CHOICE OF PRETREATMENT AGENTS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     General approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;For reasons discussed above, pretreatment should be viewed as a supplementary (ie, nonessential) step in rapid sequence intubation (RSI). In appropriate clinical circumstances, the pretreatment approaches described here may be beneficial. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Pretreatment medications and their indications'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Asthma (elevated airway resistance)",
"    </span>",
"    &nbsp;&mdash;&nbsp;To reduce airway resistance in adults requiring urgent intubation for reactive airway disease, we suggest pretreatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    . The lidocaine dose is 1.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    intravenously (IV), given two to three minutes before intubation. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Lidocaine'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Elevated intracranial pressure",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest pretreatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    and an ultrashort-acting opioid (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/52/38730?source=see_link\">",
"     fentanyl",
"    </a>",
"    ) in patients who require urgent intubation due to a condition that can be exacerbated by an elevation in intracranial pressure. Such conditions may include stroke, intracranial hemorrhage, meningitis or encephalitis, traumatic brain injury, cerebral edema, and hypertensive encephalopathy.",
"   </p>",
"   <p>",
"    The",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    dose is 1.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    IV, given two to three minutes before intubation. An ultrashort-acting opioid should NOT be given as a pretreatment agent to a patient with significant hemodynamic instability because of the risk of a further decline in blood pressure. The",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/52/38730?source=see_link\">",
"     fentanyl",
"    </a>",
"    dose is 3",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    IV given over 30 to 60 seconds approximately three minutes before the induction medication is administered. Fentanyl should be the last pretreatment drug given. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Lidocaine'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H6\">",
"     'Ultrashort-acting opioid'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Cardiovascular emergencies",
"    </span>",
"    &nbsp;&mdash;&nbsp;To prevent sudden increases in heart rate or blood pressure in patients requiring urgent intubation during a cardiovascular emergency (eg, acute coronary syndrome, aortic dissection), or for emergent intubation of patients with known severe cardiovascular disease (eg, recent myocardial infarction or episodes of angina pectoris), we suggest pretreatment with an ultrashort-acting opioid (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/52/38730?source=see_link\">",
"     fentanyl",
"    </a>",
"    ). An ultrashort-acting opioid should NOT be given to a patient with shock or significant hemodynamic instability. The fentanyl dose is 3",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    IV given over 30 to 60 seconds approximately three minutes before the induction medication is administered. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Ultrashort-acting opioid'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Performing laryngoscopy and placing an endotracheal tube stimulate the sympathetic and parasympathetic nerves of the upper airway causing reflexive actions to protect the airway, such as gagging and coughing, as well as increases in blood pressure, and intracranial pressure. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Physiologic responses to laryngoscopy and intubation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pretreatment should be viewed as a supplementary (ie, nonessential) step in rapid sequence intubation (RSI). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Pretreatment medications and their indications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The mnemonic \"ABC\" may help practitioners recall the conditions under which pretreatment may be used: high airway resistance (\"Asthma\"), high intracranial pressure and pediatric intubations (\"Brains and Babies\"), and specific cardiovascular conditions (\"Cardiovascular\").",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?11/23/11640?source=see_link\">",
"       Atropine",
"      </a>",
"      should be readily available as a rescue medication if bradycardia occurs but is",
"      <strong>",
"       not",
"      </strong>",
"      used for pretreatment in adults. Atropine pretreatment may be helpful in young children; this is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/29/24026?source=see_link\">",
"       \"Rapid sequence intubation (RSI) in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We suggest pretreatment with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/34/35360?source=see_link\">",
"       lidocaine",
"      </a>",
"      to reduce airway resistance in adults requiring urgent intubation for severe reactive airway disease (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Lidocaine'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest pretreatment with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/34/35360?source=see_link\">",
"       lidocaine",
"      </a>",
"      and an ultrashort-acting opioid (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/52/38730?source=see_link\">",
"       fentanyl",
"      </a>",
"      ) in patients who require urgent intubation due to a condition that can be exacerbated by an elevation in intracranial pressure (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Such conditions may include stroke, intracranial hemorrhage, meningitis or encephalitis, traumatic brain injury, and hypertensive encephalopathy. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Ultrashort-acting opioid'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend pretreatment with an ultrashort-acting opioid (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/52/38730?source=see_link\">",
"       fentanyl",
"      </a>",
"      ) to prevent sudden increases in heart rate or blood pressure in patients requiring urgent intubation during a cardiovascular emergency (eg, acute coronary syndrome, aortic dissection) (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). An ultrashort-acting opioid should",
"      <strong>",
"       NOT",
"      </strong>",
"      be given to a patient with shock or significant hemodynamic instability.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/55/38775/abstract/1\">",
"      Choyce A, Avidan MS, Harvey A, et al. The cardiovascular response to insertion of the intubating laryngeal mask airway. Anaesthesia 2002; 57:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/55/38775/abstract/2\">",
"      Kihara S, Brimacombe J, Yaguchi Y, et al. Hemodynamic responses among three tracheal intubation devices in normotensive and hypertensive patients. Anesth Analg 2003; 96:890.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/55/38775/abstract/3\">",
"      Tong JL, Ashworth DR, Smith JE. Cardiovascular responses following laryngoscope assisted, fibreoptic orotracheal intubation. Anaesthesia 2005; 60:754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/55/38775/abstract/4\">",
"      Xue FS, Liao X, Liu KP, et al. The circulatory responses to tracheal intubation in children: a comparison of the oral and nasal routes. Anaesthesia 2007; 62:220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/55/38775/abstract/5\">",
"      Xue FS, Zhang GH, Sun HY, et al. Blood pressure and heart rate changes during intubation: a comparison of direct laryngoscopy and a fibreoptic method. Anaesthesia 2006; 61:444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/55/38775/abstract/6\">",
"      Kerr ME, Rudy EB, Weber BB, et al. Effect of short-duration hyperventilation during endotracheal suctioning on intracranial pressure in severe head-injured adults. Nurs Res 1997; 46:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/55/38775/abstract/7\">",
"      Rudy EB, Turner BS, Baun M, et al. Endotracheal suctioning in adults with head injury. Heart Lung 1991; 20:667.",
"     </a>",
"    </li>",
"    <li>",
"     Caro DA, Bush S. Pretreatment agents. In: Manual of Emergency Airway Management, 3rd, Walls RM, Murphy MF.  (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2008.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/55/38775/abstract/9\">",
"      Clancy M, Halford S, Walls R, Murphy M. In patients with head injuries who undergo rapid sequence intubation using succinylcholine, does pretreatment with a competitive neuromuscular blocking agent improve outcome? A literature review. Emerg Med J 2001; 18:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/55/38775/abstract/10\">",
"      McCauley CS, Boller LR. Bradycardic responses to endotracheal suctioning. Crit Care Med 1988; 16:1165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/55/38775/abstract/11\">",
"      S&oslash;rensen M, Engbaek J, Viby-Mogensen J, et al. Bradycardia and cardiac asystole following a single injection of suxamethonium. Acta Anaesthesiol Scand 1984; 28:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/55/38775/abstract/12\">",
"      Viby-Mogensen J, Wisborg K, S&oslash;rensen O. Cardiac effects of atropine and gallamine in patients receiving suxamethonium. Br J Anaesth 1980; 52:1137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/55/38775/abstract/13\">",
"      Cozanitis DA, Dundee JW, Khan MM. Comparative study of atropine and glycopyrrolate on suxamethonium-induced changes in cardiac rate and rhythm. Br J Anaesth 1980; 52:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/55/38775/abstract/14\">",
"      Magee DA, Sweet PT, Holland AJ. Effect of atropine on bradydysrhythmias induced by succinylcholine following pretreatment with D-tubocurarine. Can Anaesth Soc J 1982; 29:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/55/38775/abstract/15\">",
"      Brandt MR, Viby-Mogensen J. Halothane anaesthesia and suxamethonium III. Atropine 30 s before a second dose of suxamethonium during inhalation anaesthesia: effects and side-effects. Acta Anaesthesiol Scand Suppl 1978; 67:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/55/38775/abstract/16\">",
"      Greenan J, Dewar M, Jones CJ. Intravenous glycopyrrolate and atropine at induction of anaesthesia: a comparison. J R Soc Med 1983; 76:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/55/38775/abstract/17\">",
"      Latorre F, Ellmauer S, Dick W. [Atropine in the premedication of patients at risk. Its effect on hemodynamics and salivation during intubation anesthesia using succinylcholine]. Anaesthesist 1992; 41:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/55/38775/abstract/18\">",
"      Shipton EA, Roelofse JA, Luus HG. Effect of intramuscular atropine and glycopyrrolate on the cardiovascular response to tracheal intubation. S Afr Med J 1984; 66:528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/55/38775/abstract/19\">",
"      Aouad MT, Sayyid SS, Zalaket MI, Baraka AS. Intravenous lidocaine as adjuvant to sevoflurane anesthesia for endotracheal intubation in children. Anesth Analg 2003; 96:1325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/55/38775/abstract/20\">",
"      Davidson JA, Gillespie JA. Tracheal intubation after induction of anaesthesia with propofol, alfentanil and i.v. lignocaine. Br J Anaesth 1993; 70:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/55/38775/abstract/21\">",
"      Jakobsen CJ, Ahlburg P, Holdg&aring;rd HO, et al. Comparison of intravenous and topical lidocaine as a suppressant of coughing after bronchoscopy during general anesthesia. Acta Anaesthesiol Scand 1991; 35:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/55/38775/abstract/22\">",
"      Lin CS, Sun WZ, Chan WH, et al. Intravenous lidocaine and ephedrine, but not propofol, suppress fentanyl-induced cough. Can J Anaesth 2004; 51:654.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/55/38775/abstract/23\">",
"      Nishino T, Hiraga K, Sugimori K. Effects of i.v. lignocaine on airway reflexes elicited by irritation of the tracheal mucosa in humans anaesthetized with enflurane. Br J Anaesth 1990; 64:682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/55/38775/abstract/24\">",
"      Pandey CK, Raza M, Ranjan R, et al. Intravenous lidocaine suppresses fentanyl-induced coughing: a double-blind, prospective, randomized placebo-controlled study. Anesth Analg 2004; 99:1696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/55/38775/abstract/25\">",
"      Pandey CK, Raza M, Ranjan R, et al. Intravenous lidocaine 0.5 mg.kg-1 effectively suppresses fentanyl-induced cough. Can J Anaesth 2005; 52:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/55/38775/abstract/26\">",
"      Warner LO, Balch DR, Davidson PJ. Is intravenous lidocaine an effective adjuvant for endotracheal intubation in children undergoing induction of anesthesia with halothane-nitrous oxide? J Clin Anesth 1997; 9:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/55/38775/abstract/27\">",
"      Yukioka H, Hayashi M, Terai T, Fujimori M. Intravenous lidocaine as a suppressant of coughing during tracheal intubation in elderly patients. Anesth Analg 1993; 77:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/55/38775/abstract/28\">",
"      Groeben H, Silvanus MT, Beste M, Peters J. Combined intravenous lidocaine and inhaled salbutamol protect against bronchial hyperreactivity more effectively than lidocaine or salbutamol alone. Anesthesiology 1998; 89:862.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/55/38775/abstract/29\">",
"      Groeben H, Silvanus MT, Beste M, Peters J. Both intravenous and inhaled lidocaine attenuate reflex bronchoconstriction but at different plasma concentrations. Am J Respir Crit Care Med 1999; 159:530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/55/38775/abstract/30\">",
"      Maslow AD, Regan MM, Israel E, et al. Inhaled albuterol, but not intravenous lidocaine, protects against intubation-induced bronchoconstriction in asthma. Anesthesiology 2000; 93:1198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/55/38775/abstract/31\">",
"      Robinson N, Clancy M. In patients with head injury undergoing rapid sequence intubation, does pretreatment with intravenous lignocaine/lidocaine lead to an improved neurological outcome? A review of the literature. Emerg Med J 2001; 18:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/55/38775/abstract/32\">",
"      Butler J, Jackson R. Towards evidence based emergency medicine: best BETs from Manchester Royal Infirmary. Lignocaine premedication before rapid sequence induction in head injuries. Emerg Med J 2002; 19:554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/55/38775/abstract/33\">",
"      Brooks D, Anderson CM, Carter MA, et al. Clinical practice guidelines for suctioning the airway of the intubated and nonintubated patient. Can Respir J 2001; 8:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/55/38775/abstract/34\">",
"      Grover VK, Reddy GM, Kak VK, Singh S. Intracranial pressure changes with different doses of lignocaine under general anaesthesia. Neurol India 1999; 47:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/55/38775/abstract/35\">",
"      White PF, Schlobohm RM, Pitts LH, Lindauer JM. A randomized study of drugs for preventing increases in intracranial pressure during endotracheal suctioning. Anesthesiology 1982; 57:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/55/38775/abstract/36\">",
"      Bachofen M. [Suppression of blood pressure increases during intubation: lidocaine or fentanyl?]. Anaesthesist 1988; 37:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/55/38775/abstract/37\">",
"      Samaha T, Ravussin P, Claquin C, Ecoffey C. [Prevention of increase of blood pressure and intracranial pressure during endotracheal intubation in neurosurgery: esmolol versus lidocaine]. Ann Fr Anesth Reanim 1996; 15:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/55/38775/abstract/38\">",
"      Yano M, Nishiyama H, Yokota H, et al. Effect of lidocaine on ICP response to endotracheal suctioning. Anesthesiology 1986; 64:651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/55/38775/abstract/39\">",
"      Chung KS, Sinatra RS, Halevy JD, et al. A comparison of fentanyl, esmolol, and their combination for blunting the haemodynamic responses during rapid-sequence induction. Can J Anaesth 1992; 39:774.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/55/38775/abstract/40\">",
"      Cork RC, Weiss JL, Hameroff SR, Bentley J. Fentanyl preloading for rapid-sequence induction of anesthesia. Anesth Analg 1984; 63:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/55/38775/abstract/41\">",
"      Dahlgren N, Messeter K. Treatment of stress response to laryngoscopy and intubation with fentanyl. Anaesthesia 1981; 36:1022.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/55/38775/abstract/42\">",
"      Kerr ME, Sereika SM, Orndoff P, et al. Effect of neuromuscular blockers and opiates on the cerebrovascular response to endotracheal suctioning in adults with severe head injuries. Am J Crit Care 1998; 7:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/55/38775/abstract/43\">",
"      Vacanti CA, Silbert BS, Vacanti FX. The effects of thiopental sodium on fentanyl-induced muscle rigidity in a human model. J Clin Anesth 1991; 3:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/55/38775/abstract/44\">",
"      Caspi J, Klausner JM, Safadi T, et al. Delayed respiratory depression following fentanyl anesthesia for cardiac surgery. Crit Care Med 1988; 16:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/55/38775/abstract/45\">",
"      Roy S, Fortier LP. Fentanyl-induced rigidity during emergence from general anesthesia potentiated by venlafexine. Can J Anaesth 2003; 50:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/55/38775/abstract/46\">",
"      Roback MG, Wathen JE, Bajaj L, Bothner JP. Adverse events associated with procedural sedation and analgesia in a pediatric emergency department: a comparison of common parenteral drugs. Acad Emerg Med 2005; 12:508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/55/38775/abstract/47\">",
"      Sacchetti A, Senula G, Strickland J, Dubin R. Procedural sedation in the community emergency department: initial results of the ProSCED registry. Acad Emerg Med 2007; 14:41.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 282 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-58.240.98.179-2FE80B8408-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_55_38775=[""].join("\n");
var outline_f37_55_38775=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H12\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PHYSIOLOGIC RESPONSES TO LARYNGOSCOPY AND INTUBATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PRETREATMENT MEDICATIONS AND THEIR INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Atropine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Lidocaine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Ultrashort-acting opioid",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      CHOICE OF PRETREATMENT AGENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      General approach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Asthma (elevated airway resistance)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Elevated intracranial pressure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Cardiovascular emergencies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/35/31288?source=related_link\">",
"      Neuromuscular blocking agents (NMBA) for rapid sequence intubation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/60/10186?source=related_link\">",
"      Neuronal control of the airways",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/29/24026?source=related_link\">",
"      Rapid sequence intubation (RSI) in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/55/1912?source=related_link\">",
"      Rapid sequence intubation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/30/11754?source=related_link\">",
"      Sedation or induction agents for rapid sequence intubation in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_55_38776="Respiratory manifestations of food allergy";
var content_f37_55_38776=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Respiratory manifestations of food allergy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/55/38776/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/55/38776/contributors\">",
"     John M James, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/55/38776/contributors\">",
"     Scott H Sicherer, MD, FAAAAI",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/55/38776/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/55/38776/contributors\">",
"     Robert A Wood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/55/38776/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/55/38776/contributors\">",
"     Elizabeth TePas, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?37/55/38776/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 17, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Respiratory tract symptoms observed with food hypersensitivity reactions include nasal congestion, rhinorrhea, sneezing, itching of the nose and throat, coughing, and wheezing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/55/38776/abstract/1\">",
"     1",
"    </a>",
"    ]. Food allergen exposure is usually through ingestion, but the inhalation of food proteins in the form of dust or aerosolized particles may also trigger respiratory symptoms.",
"   </p>",
"   <p>",
"    Isolated asthma or rhinitis secondary to food allergy is reported, but is rare [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/55/38776/abstract/2\">",
"     2",
"    </a>",
"    ]. More commonly, respiratory symptoms of food allergy are accompanied by skin",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    gastrointestinal manifestations. Foods can elicit asymptomatic airway hyperreactivity or symptomatic asthmatic responses. In addition, systemic anaphylactic reactions often have a respiratory component.",
"   </p>",
"   <p>",
"    This topic covers the etiology, diagnosis, and clinical manifestations of respiratory symptoms related to food allergy. Other clinical manifestations of food allergy, oral allergy syndrome, and food-induced anaphylaxis are discussed separately. Occupational asthma and rhinitis are discussed in more detail elsewhere (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/29/14808?source=see_link\">",
"     \"Clinical manifestations of food allergy: An overview\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/52/11082?source=see_link\">",
"     \"Clinical manifestations and diagnosis of oral allergy syndrome (pollen-food allergy syndrome)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/0/38920?source=see_link\">",
"     \"Food-induced anaphylaxis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/48/7945?source=see_link\">",
"     \"Occupational rhinitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/0/34824?source=see_link\">",
"     \"Occupational asthma: Definitions, epidemiology, causes, and risk factors\"",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;This section reviews the prevalence of respiratory manifestations of food allergy and examines several associations between food allergy and asthma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Prevalence",
"    </span>",
"    &nbsp;&mdash;&nbsp;The public perception of food allergy, including food allergy-induced asthma, is disproportionate to its actual prevalence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/55/38776/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. Suspected cases of food allergies are often not confirmed when objective investigations, including food challenges, are undertaken [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/55/38776/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. While respiratory symptoms as a component of systemic allergic reactions triggered by food occur in almost one half of patients, isolated food-induced respiratory symptoms are rare.",
"   </p>",
"   <p>",
"    The prevalence of respiratory symptoms in patients with food allergies have been reported in several studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A population study in France found the overall prevalence of food allergy was approximately 3 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/55/38776/abstract/7\">",
"       7",
"      </a>",
"      ]. Rhinitis and asthma were each reported as symptoms during food allergy reactions in 6 percent of cases. Asthma was the most common manifestation of food allergy in children four to six years of age.",
"     </li>",
"     <li>",
"      Another investigation summarized data from a voluntary registry of 5149 individuals (median age: five years) with peanut",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      tree nut allergy in the United States [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/55/38776/abstract/8\">",
"       8",
"      </a>",
"      ]. Respiratory reactions, including wheezing, throat tightness, and nasal congestion, were reported as part of the initial reaction in approximately half of respondents. Registrants with asthma were significantly more likely than those without asthma to have severe reactions (33 versus 21 percent).",
"     </li>",
"     <li>",
"      A random telephone survey estimated the prevalence of seafood allergy in the United States [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/55/38776/abstract/9\">",
"       9",
"      </a>",
"      ]. Fish or shellfish allergy was reported in 6 percent of households",
"      <span class=\"nowrap\">",
"       (326/5529)",
"      </span>",
"      and 2 percent",
"      <span class=\"nowrap\">",
"       (344/11,948)",
"      </span>",
"      of individuals. Shortness of breath and throat tightness were reported by more than 50 percent of those with seafood allergy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other studies have examined the prevalence of food allergy or sensitization in patients with asthma or respiratory symptoms:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Seventeen percent",
"      <span class=\"nowrap\">",
"       (114/669)",
"      </span>",
"      of a random selection of adults who responded to the European Community Respiratory Health Survey (ECRHS) questionnaire in Melbourne, Australia reported food intolerance or allergy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/55/38776/abstract/10\">",
"       10",
"      </a>",
"      ]. Only 7 percent",
"      <span class=\"nowrap\">",
"       (8/114)",
"      </span>",
"      had isolated respiratory symptoms triggered by a particular food.",
"     </li>",
"     <li>",
"      The incidence of food-allergy triggered respiratory symptoms was 2 to 8 percent in studies from Hungary and France of children and adults with asthma [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/55/38776/abstract/11-13\">",
"       11-13",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     ASSOCIATIONS BETWEEN FOOD ALLERGY AND ASTHMA",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to respiratory symptoms occurring as a presentation of food allergy, patients with food allergy are at increased risk for developing asthma, and often severe asthma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Atopic march",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with a family history of atopy and sensitization to food proteins in early infancy are at high risk of subsequent respiratory allergic disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/55/38776/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Egg allergy in infancy has been reported to predict respiratory allergic disease by four years of age [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/55/38776/abstract/15\">",
"       15",
"      </a>",
"      ]. Two percent of children in a cohort of 1218 consecutive births followed until four years of age developed egg allergy. Increased risk of respiratory allergy (rhinitis or asthma) was associated with egg allergy (OR = 5.0, 95% CI 1.1-22.3), with a positive predictive value of 55 percent. Furthermore, the presence of eczema in association with egg allergy increased the positive predictive value to 80 percent.",
"     </li>",
"     <li>",
"      Another prospective cohort study of 100 infants at risk for asthma and atopy found that skin sensitivity to hen's egg, cow's milk, or both in the first five years of life was predictive of asthma (OR = 10.7, 95% CI 2.1-55.1) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/55/38776/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Investigators followed 271 children over six years of age and 296 children less than six years from a family-based food allergy cohort in Chicago, IL [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/55/38776/abstract/17\">",
"       17",
"      </a>",
"      ]. Food allergy status was determined based upon the type and timing of clinical symptoms after ingestion of a specific food and results of specific IgE to foods using prick skin testing and allergen-specific IgE. Symptomatic food allergy was associated with asthma in both older (odds ratio (OR) = 4.9, 95% confidence interval (CI): 2.5-9.5) and younger children (OR = 5.3, 95% CI: 1.7-16.2). The association was stronger among children with multiple or severe food allergies, especially in older children. Children with food allergy developed asthma earlier and at higher prevalence than children without food allergy. There was a significant association between food allergy and asthma.",
"     </li>",
"     <li>",
"      A case-control study was conducted with 69 children (ages: 7.2 to 13.3 years) with allergy to egg (n = 60)",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      fish (n = 29) in the first three years of life [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/55/38776/abstract/18\">",
"       18",
"      </a>",
"      ]. Asthma symptoms were reported more frequently in the study group than in control subjects (154 children, 70 of whom had aeroallergen sensitization, but no food allergy). In addition, study patients showed a significantly increased frequency of positive responses to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/32/10756?source=see_link\">",
"       methacholine",
"      </a>",
"      challenge compared to controls.",
"     </li>",
"     <li>",
"      Based upon a sample of 8203 participants in the National Health and Nutrition Examination survey 2005 to 2006, where serologic tests were used to estimate food allergy prevalence, having a likely food allergy was associated with an adjusted odds ratio of 3.8 (95% confidence interval (CI), 1.5-10.7) for having current asthma and 6.9 (95% confidence interval (CI), 2.4-19.7) for having had an emergency department visit for asthma in the preceding year [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/55/38776/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Marker for asthma severity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Food allergen sensitivity may also be a marker for increased asthma severity.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Food allergen sensitization was examined in inner city children in the United States with asthma [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/55/38776/abstract/20\">",
"       20",
"      </a>",
"      ]. In vitro specific IgE testing to six common food allergens (egg, milk, soy, peanut, wheat, and fish) was performed. Forty-five percent of the children were sensitized to at least one food. Children sensitized to foods had higher rates of hospitalization for asthma exacerbations and required more treatment with glucocorticoids.",
"     </li>",
"     <li>",
"      Nineteen children with severe exacerbations of asthma requiring mechanical ventilation were investigated [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/55/38776/abstract/21\">",
"       21",
"      </a>",
"      ]. These patients had an increased risk of food allergy (OR 8.6, 95% CI 1.8-39.7) and frequent asthma admissions (OR 14.2, 1.8-113.6) compared with controls. Fifty percent of the cases had food allergy versus ten percent of the controls.",
"     </li>",
"     <li>",
"      Another group studied a cohort of 203 inner city adults (mean age 48 years) with persistent asthma. Patients with self-reported allergies to more than one food had increased asthma hospitalizations, emergency department visits for asthma, and use of oral glucocorticoids [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/55/38776/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Marker for fatal anaphylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Food-induced respiratory symptoms, especially asthma, are a risk factor for fatal and near-fatal anaphylactic reactions. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/13/1241?source=see_link\">",
"     \"Fatal anaphylaxis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of different food allergens can induce respiratory symptoms, via ingestion",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    inhalation routes of exposure. In children, sensitization may occur through the gastrointestinal tract or possibly the skin. Factors favoring the acquisition of food allergy with respiratory manifestations in adulthood include sensitization to pollens and occupational exposure by inhalation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/55/38776/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/42/43689?source=see_link\">",
"     \"Pathogenesis of food allergy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Routes of exposure",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Ingestion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oral ingestion is the primary route of exposure to foods that can cause or exacerbate respiratory symptoms. An internet-based survey of 51 anaphylactic reactions to foods showed that while most of these reactions (78 percent) occurred after ingestion, 16 percent occurred following exclusive skin contact and 6 percent occurred after inhalation of the food allergen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/55/38776/abstract/25\">",
"     25",
"    </a>",
"    ]. These reactions will be discussed in more detail below. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Respiratory manifestations'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Inhalation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several investigations have highlighted cases of respiratory allergic disease precipitated by inhalation of airborne food allergens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/55/38776/abstract/26-38\">",
"     26-38",
"    </a>",
"    ]. These exposures occur in both occupational and nonoccupational settings. Prolonged exposure to high levels of food allergens, such as occurs in occupational settings, increases the risk of sensitization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/55/38776/abstract/39\">",
"     39",
"    </a>",
"    ]. Occupational exposures to airborne food allergens can also result in chronic asthma.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Highly allergic persons may react when exposed to aerosolized allergen in a seafood restaurant [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/55/38776/abstract/26\">",
"       26",
"      </a>",
"      ]. Exposure to airborne fish allergens can also occur at open-air fish markets [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/55/38776/abstract/28,37,38\">",
"       28,37,38",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Asthma symptoms can occur in sensitized children when food allergens such as fish, shellfish, eggs, chickpeas, or buckwheat are cooked in a confined area [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/55/38776/abstract/27-29\">",
"       27-29",
"      </a>",
"      ]. Both acute and late-phase respiratory symptoms were demonstrated in one of these studies [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/55/38776/abstract/29\">",
"       29",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Several cases were reported of patients who developed asthma and rhinitis when exposed to raw, but not cooked, green beans and chard while preparing these vegetables for cooking in a nonoccupational environment [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/55/38776/abstract/28,37,38\">",
"       28,37,38",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Chronic respiratory symptoms occurring only at work were reported in a restaurant cook whose job consisted solely of preparing and cutting raw meat [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/55/38776/abstract/30\">",
"       30",
"      </a>",
"      ]. Another patient had recurrent episodes of anaphylaxis with severe respiratory symptoms that occurred when cutting raw meat at home.",
"     </li>",
"     <li>",
"      Baker's asthma is caused by occupational exposure to airborne cereal grain or soybean dust [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/55/38776/abstract/31,32\">",
"       31,32",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Bakery workers may also develop IgE-mediated respiratory symptoms to liquid and aerosolized hen's egg proteins that are commonly used in the baking and confectionery industries [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/55/38776/abstract/33\">",
"       33",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Occupational asthma is reported in people with egg allergy who work in egg-processing factories [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/55/38776/abstract/34\">",
"       34",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These data highlight the importance of considering foods as aeroallergens in patients with coexistent food allergy and allergic asthma. Dietary avoidance alone may not be sufficient for these individuals. Further environmental measures may be required to limit exposure to aerosolized food. Additional information about the risks and avoidance strategies regarding inhalational exposure are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/48/18185?source=see_link\">",
"     \"Management of food allergy: Avoidance\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Allergens",
"    </span>",
"    &nbsp;&mdash;&nbsp;A short list of specific foods trigger most food hypersensitivity reactions involving the respiratory tract [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/55/38776/abstract/2,5,40-44\">",
"     2,5,40-44",
"    </a>",
"    ]. These foods include peanut, tree nuts, fish, shellfish, hen's egg, cow's milk, and seeds. Reactions to these foods usually occur after ingestion, but can also occur after inhalation.",
"   </p>",
"   <p>",
"    Anaphylactic reactions to foods, including significant respiratory symptoms, are most often caused by peanut, tree nuts, or seafood [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/55/38776/abstract/45\">",
"     45",
"    </a>",
"    ]. Respiratory reactions, including wheezing, throat tightness, and nasal congestion, occur in approximately 50 percent of initial reactions to peanut or tree nuts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/55/38776/abstract/8\">",
"     8",
"    </a>",
"    ]. A similar percentage of patients with fish or shellfish allergy report respiratory symptoms with exposure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/55/38776/abstract/9\">",
"     9",
"    </a>",
"    ]. The presence of asthma is a risk factor for more severe reactions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/55/38776/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/0/38920?source=see_link\">",
"     \"Food-induced anaphylaxis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other food allergens have been implicated as a cause for upper and lower respiratory tract symptoms secondary to food hypersensitivity by the inhalation route, as opposed to the ingestion route [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/55/38776/abstract/46\">",
"     46",
"    </a>",
"    ]. The most common example is baker's asthma triggered by occupational exposure to wheat [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/55/38776/abstract/47\">",
"     47",
"    </a>",
"    ]. Additional foods include carrot [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/55/38776/abstract/48\">",
"     48",
"    </a>",
"    ], lupine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/55/38776/abstract/49,50\">",
"     49,50",
"    </a>",
"    ], asparagus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/55/38776/abstract/51\">",
"     51",
"    </a>",
"    ], and soybean [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/55/38776/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A high percentage of patients with asthma perceive that food additives worsen their respiratory symptoms. However, blinded challenges often do not confirm these triggers. Several different food additives, including sulfites and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?32/6/32866?source=see_link\">",
"     sodium benzoate",
"    </a>",
"    , have been implicated in adverse respiratory reactions. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/46/40681?source=see_link\">",
"     \"Allergic and asthmatic reactions to food additives\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The medical history supplemented with appropriate laboratory testing and food challenges can provide useful information in evaluating patients with respiratory symptoms that may be induced by food allergy. Further workup for IgE-mediated allergy is not generally indicated if no specific foods are implicated in the history and if skin tests or in vitro measurements of specific IgE to foods are negative.",
"   </p>",
"   <p>",
"    Food is unlikely to be the problem if respiratory symptoms persist after food elimination diets are implemented. Respiratory symptoms that recur after a regular diet has been resumed should be evaluated with a food challenge. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/17/26904?source=see_link\">",
"     \"History and physical examination in the patient with possible food allergy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/12/5321?source=see_link\">",
"     \"Diagnostic evaluation of food allergy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/59/20409?source=see_link\">",
"     \"Oral food challenges for diagnosis and management of food allergies\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Studies have demonstrated that foods can elicit airway hyperreactivity and asthmatic responses. Thus, evaluation for food allergy should be considered in patients with:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Recalcitrant or otherwise unexplained acute, severe asthma exacerbations",
"     </li>",
"     <li>",
"      Asthma exacerbations following ingestion or inhalation of particular foods",
"     </li>",
"     <li>",
"      Asthma and other manifestations of food allergy (eg, anaphylaxis, moderate to severe atopic dermatitis)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     RESPIRATORY MANIFESTATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Upper respiratory symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nasal symptoms are commonly seen as part of systemic food-triggered allergic reactions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/55/38776/abstract/2,53\">",
"     2,53",
"    </a>",
"    ]. However, isolated rhinitis in response to foods is rare. An exception is occupational rhinitis in food-industry workers. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/48/7945?source=see_link\">",
"     \"Occupational rhinitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    These points are illustrated by two studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one series, 320 children and young adults with atopic dermatitis, half of whom also had asthma and allergic rhinitis, underwent double-blind placebo-controlled food challenges (DBPCFCs). Sixty-four percent of the patients had at least one positive challenge, and out of these, 59 percent experienced respiratory symptoms. Seventy percent of the overall respiratory symptoms observed included rhinitis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/55/38776/abstract/53\">",
"       53",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In another series, 480 patients with a history of an adverse reaction to food also underwent DBPCFCs. Positive challenges were observed in 39 percent, and 51 percent of those had upper",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      lower respiratory symptoms. Nasal symptoms included congestion, sneezing, and rhinorrhea. Isolated respiratory symptoms occurred in only 7 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/55/38776/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Many patients associate the ingestion of cow's milk and other dairy products with an increase in the production and thickness of nasal secretions. However, objective studies do not support these complaints, and they are unlikely to be due to a specific allergic reaction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/55/38776/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The role of food allergy in recurrent serious otitis media has been proposed but this association is controversial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/55/38776/abstract/55,56\">",
"     55,56",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Asthma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most studies regarding food allergy and respiratory tract symptoms have focused on patients with an underlying history of asthma. The potential role of food allergy in triggering asthma symptoms has been highlighted in practice parameters for the diagnosis and treatment of asthma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/55/38776/abstract/57\">",
"     57",
"    </a>",
"    ]. The association between food allergy and asthmatic symptoms is seen mainly in children, especially those with atopic dermatitis, and occurs primarily after ingestion of the food allergen. In adults, isolated asthma as a manifestation of food allergy is most commonly related to inhalation exposure and is seen primarily in food-industry workers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/55/38776/abstract/58,59\">",
"     58,59",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/0/34824?source=see_link\">",
"     \"Occupational asthma: Definitions, epidemiology, causes, and risk factors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/15/36089?source=see_link\">",
"     \"Occupational asthma: Clinical features and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Food-induced asthma in children was demonstrated in the following studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Two to 10 percent of children with asthma were reported to have respiratory symptoms related to food allergy in several European and Eurasian studies [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/55/38776/abstract/11,60-63\">",
"       11,60-63",
"      </a>",
"      ]. Asthma as the sole symptom during a positive food challenge was rare. Allergic sensitization typically occurred in the first year of life. Reactions were usually caused by a single food, most often peanut, hen's egg, cow's milk, or fish.",
"     </li>",
"     <li>",
"      In a United States study of children with asthma, one-quarter of the children with a history of food-induced asthma had wheezing during positive blinded food challenges [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/55/38776/abstract/64\">",
"       64",
"      </a>",
"      ]. The most common foods that were responsible for these reactions included peanut, cow's milk, hen's egg, and tree nuts. Only 2 percent had wheezing as their only objective symptom.",
"      <br/>",
"      <br/>",
"      Bronchospastic respiratory symptoms are also seen in children with atopic dermatitis and food allergy when they undergo food challenges. Respiratory symptoms are less commonly seen in children with non-IgE mediated food allergy with primarily gastrointestinal manifestations.",
"     </li>",
"     <li>",
"      In an Italian series, 27 percent",
"      <span class=\"nowrap\">",
"       (11/42)",
"      </span>",
"      of young children with atopic dermatitis and milk allergy developed asthmatic symptoms during a positive food challenge [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/55/38776/abstract/65\">",
"       65",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      An Australian group reported on 100 children (mean age: 16 months) who had clinical histories of adverse reactions to cow's milk [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/55/38776/abstract/66\">",
"       66",
"      </a>",
"      ]. The children were separated into three distinct groups based upon symptoms. Among children who had acute cutaneous reactions upon ingestion of cow's milk and had cow milk-specific IgE antibodies, 29 percent had lower airway responses on oral challenges. In a second group with primarily non-IgE-mediated gastrointestinal reactions to cow's milk challenges, only 4 percent experienced lower airway symptoms. The majority of patients in the third group with late onset reactions to oral challenges with cow's milk had chronic asthma or atopic dermatitis, and 50 percent developed wheezing after the milk challenge.",
"     </li>",
"     <li>",
"      In a previously-cited United States study, children with atopic dermatitis undergoing blinded food challenges were monitored for respiratory reactions [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/55/38776/abstract/53\">",
"       53",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Upper respiratory symptoms'",
"      </a>",
"      above.) Seventeen percent of children developed wheezing during positive food challenges. Eighty-eight patients were monitored with pulmonary function testing during food challenges. Fifteen percent",
"      <span class=\"nowrap\">",
"       (13/88)",
"      </span>",
"      developed lower respiratory symptoms, including wheezing. However, only six patients had a &gt;20 percent decrease in FEV1. Wheezing as the only manifestation of the respiratory reaction was a rare observation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Baker's asthma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adults more commonly have food allergy induced respiratory symptoms from inhalation exposure. These exposures typically occur in occupational settings. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/0/34824?source=see_link\">",
"     \"Occupational asthma: Definitions, epidemiology, causes, and risk factors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/15/36089?source=see_link\">",
"     \"Occupational asthma: Clinical features and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A classic example is baker's asthma, which is most commonly associated with wheat allergy, although other food allergen triggers are reported:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A significant percentage of bakers develop occupational asthma and chronic obstructive bronchitis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/55/38776/abstract/31\">",
"       31",
"      </a>",
"      ]. Positive",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/32/10756?source=see_link\">",
"       methacholine",
"      </a>",
"      tests were seen in 33 percent of bakers with atopic status, compared with 6 percent of non-atopic bakers.",
"     </li>",
"     <li>",
"      A small study found that bakery workers with a positive skin test to wheat may develop IgE-mediated respiratory symptoms upon bronchial challenge test with wheat flour [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/55/38776/abstract/67\">",
"       67",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Bakery workers may develop IgE-mediated occupational asthma to soybean flour as well. The allergens involved are predominantly high molecular weight proteins that are present both in soybean hull and flour [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/55/38776/abstract/32\">",
"       32",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      IgE-mediated asthma can also be triggered by liquid and aerosolized hen's egg proteins that are commonly used in the baking and confectionery industries [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/55/38776/abstract/33\">",
"       33",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Airway hyperresponsiveness",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ingestion of a food to which the patient is allergic may result in increased airway hyperresponsiveness (AHR) despite the absence of acute symptoms. This has been demonstrated in pediatric patients with moderate to severe asthma.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one investigation, 26 children with asthma and food allergy were evaluated using",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/32/10756?source=see_link\">",
"       methacholine",
"      </a>",
"      inhalation challenges before and after blinded food challenges [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/55/38776/abstract/68\">",
"       68",
"      </a>",
"      ]. Twelve of the 22 patients with positive food challenges had respiratory symptoms (cough, laryngeal reactions,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      wheezing). The remainder of children with positive food challenges exhibited laryngeal, gastrointestinal,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      skin symptoms without lower respiratory symptoms. Significant increases in AHR were documented in seven of the 12 patients who experienced respiratory symptoms during these challenges. Increased AHR was also noted in one patient without respiratory symptoms during a positive challenge and one patient after a negative challenge.",
"     </li>",
"     <li>",
"      Food allergy is less likely as a cause of increased AHR in adults than in children. As an example, in a study of eleven adults with asthma, a history of food-induced wheezing, and positive prick skin tests to the suspected foods, an equal number of patients had increased AHR by",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/32/10756?source=see_link\">",
"       methacholine",
"      </a>",
"      inhalation challenges after blinded food challenges to either food allergen or placebo [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/55/38776/abstract/69\">",
"       69",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Two small studies indicate that 40 to 50 percent of patients with food allergy in the absence of asthma might also have increased AHR [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/55/38776/abstract/70,71\">",
"       70,71",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Anaphylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anaphylactic reactions that include respiratory symptoms can occur after the oral ingestion of a food allergen. This topic is covered in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/0/38920?source=see_link\">",
"     \"Food-induced anaphylaxis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?28/47/29429?source=see_link\">",
"       \"Patient information: Food allergy symptoms and diagnosis (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Respiratory tract symptoms observed with food hypersensitivity reactions include nasal congestion, rhinorrhea, sneezing, itching of the nose and throat, coughing, and wheezing. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Respiratory symptoms as a component of systemic allergic reactions triggered by food occur in up to 50 percent of patients. Isolated food-induced respiratory symptoms occur in only 2 to 8 percent of food-allergic individuals. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Allergic sensitization to hen's egg",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      cow's milk in the first few years of life may be predictive of later respiratory allergic disease, including allergic rhinitis and asthma. Food allergen sensitivity may also be a marker for increased asthma severity. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Associations between food allergy and asthma'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Food allergen exposure is usually through ingestion, but the inhalation of food proteins in the form of dust or aerosolized particles may also trigger respiratory symptoms. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Etiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most common foods that trigger food hypersensitivity reactions involving the respiratory tract are peanut, tree nuts, fish, shellfish, hen's egg, cow's milk, and seeds. Wheat and soybean are the most frequently implicated food allergens in inhalation induced reactions, although hen&rsquo;s egg and seafood can also cause these types of reactions. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Allergens'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Isolated asthma or rhinitis secondary to food allergy is rare. Respiratory symptoms of food allergy more commonly are accompanied by skin",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      gastrointestinal manifestations. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Respiratory manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Food-induced asthma is more common in young pediatric patients, especially those with atopic dermatitis, than in older children or adults. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Asthma'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Occupational asthma develops in approximately 10 to 20 percent of bakers exposed to flour-related antigens. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Baker's asthma'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Ingestion of a food to which the patient is allergic may result in increased airway hyperresponsiveness (AHR) despite the absence of acute symptoms. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Airway hyperresponsiveness'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/55/38776/abstract/1\">",
"      Sampson HA. Food allergy. Part 1: immunopathogenesis and clinical disorders. J Allergy Clin Immunol 1999; 103:717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/55/38776/abstract/2\">",
"      Bock SA, Atkins FM. Patterns of food hypersensitivity during sixteen years of double-blind, placebo-controlled food challenges. J Pediatr 1990; 117:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/55/38776/abstract/3\">",
"      Nowak-Wegrzyn A, Sampson HA. Adverse reactions to foods. Med Clin North Am 2006; 90:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/55/38776/abstract/4\">",
"      Woods RK, Weiner J, Abramson M, et al. Patients' perceptions of food-induced asthma. Aust N Z J Med 1996; 26:504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/55/38776/abstract/5\">",
"      Bock SA. Prospective appraisal of complaints of adverse reactions to foods in children during the first 3 years of life. Pediatrics 1987; 79:683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/55/38776/abstract/6\">",
"      Jansen JJ, Kardinaal AF, Huijbers G, et al. Prevalence of food allergy and intolerance in the adult Dutch population. J Allergy Clin Immunol 1994; 93:446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/55/38776/abstract/7\">",
"      Kanny G, Moneret-Vautrin DA, Flabbee J, et al. Population study of food allergy in France. J Allergy Clin Immunol 2001; 108:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/55/38776/abstract/8\">",
"      Sicherer SH, Furlong TJ, Mu&ntilde;oz-Furlong A, et al. A voluntary registry for peanut and tree nut allergy: characteristics of the first 5149 registrants. J Allergy Clin Immunol 2001; 108:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/55/38776/abstract/9\">",
"      Sicherer SH, Mu&ntilde;oz-Furlong A, Sampson HA. Prevalence of seafood allergy in the United States determined by a random telephone survey. J Allergy Clin Immunol 2004; 114:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/55/38776/abstract/10\">",
"      Woods RK, Abramson M, Raven JM, et al. Reported food intolerance and respiratory symptoms in young adults. Eur Respir J 1998; 11:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/55/38776/abstract/11\">",
"      Onorato J, Merland N, Terral C, et al. Placebo-controlled double-blind food challenge in asthma. J Allergy Clin Immunol 1986; 78:1139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/55/38776/abstract/12\">",
"      N&eacute;k&aacute;m KL. Nutritional triggers in asthma. Acta Microbiol Immunol Hung 1998; 45:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/55/38776/abstract/13\">",
"      Ozol D, Mete E. Asthma and food allergy. Curr Opin Pulm Med 2008; 14:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/55/38776/abstract/14\">",
"      Peroni DG, Chatzimichail A, Boner AL. Food allergy: what can be done to prevent progression to asthma? Ann Allergy Asthma Immunol 2002; 89:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/55/38776/abstract/15\">",
"      Tariq SM, Matthews SM, Hakim EA, Arshad SH. Egg allergy in infancy predicts respiratory allergic disease by 4 years of age. Pediatr Allergy Immunol 2000; 11:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/55/38776/abstract/16\">",
"      Rhodes HL, Sporik R, Thomas P, et al. Early life risk factors for adult asthma: a birth cohort study of subjects at risk. J Allergy Clin Immunol 2001; 108:720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/55/38776/abstract/17\">",
"      Schroeder A, Kumar R, Pongracic JA, et al. Food allergy is associated with an increased risk of asthma. Clin Exp Allergy 2009; 39:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/55/38776/abstract/18\">",
"      Priftis KN, Mermiri D, Papadopoulou A, et al. Asthma symptoms and bronchial reactivity in school children sensitized to food allergens in infancy. J Asthma 2008; 45:590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/55/38776/abstract/19\">",
"      Liu AH, Jaramillo R, Sicherer SH, et al. National prevalence and risk factors for food allergy and relationship to asthma: results from the National Health and Nutrition Examination Survey 2005-2006. J Allergy Clin Immunol 2010; 126:798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/55/38776/abstract/20\">",
"      Wang J, Visness CM, Sampson HA. Food allergen sensitization in inner-city children with asthma. J Allergy Clin Immunol 2005; 115:1076.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/55/38776/abstract/21\">",
"      Roberts G, Patel N, Levi-Schaffer F, et al. Food allergy as a risk factor for life-threatening asthma in childhood: a case-controlled study. J Allergy Clin Immunol 2003; 112:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/55/38776/abstract/22\">",
"      Berns SH, Halm EA, Sampson HA, et al. Food allergy as a risk factor for asthma morbidity in adults. J Asthma 2007; 44:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/55/38776/abstract/23\">",
"      Madsen C. Prevalence of food allergy: an overview. Proc Nutr Soc 2005; 64:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/55/38776/abstract/24\">",
"      Moneret-Vautrin DA, Morisset M. Adult food allergy. Curr Allergy Asthma Rep 2005; 5:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/55/38776/abstract/25\">",
"      Eigenmann PA, Zamora SA. An internet-based survey on the circumstances of food-induced reactions following the diagnosis of IgE-mediated food allergy. Allergy 2002; 57:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/55/38776/abstract/26\">",
"      Goetz DW, Whisman BA. Occupational asthma in a seafood restaurant worker: cross-reactivity of shrimp and scallops. Ann Allergy Asthma Immunol 2000; 85:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/55/38776/abstract/27\">",
"      Sicherer SH. Is food allergy causing your patient's asthma symptoms. J Respir Dis 2000; 21:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/55/38776/abstract/28\">",
"      Crespo JF, Pascual C, Dominguez C, et al. Allergic reactions associated with airborne fish particles in IgE-mediated fish hypersensitive patients. Allergy 1995; 50:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/55/38776/abstract/29\">",
"      Roberts G, Golder N, Lack G. Bronchial challenges with aerosolized food in asthmatic, food-allergic children. Allergy 2002; 57:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/55/38776/abstract/30\">",
"      Tonnel AB, Tillie-Leblond I, Botelho AD, et al. Severe acute asthma associated with raw meat cutting. Ann Allergy Asthma Immunol 2009; 102:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/55/38776/abstract/31\">",
"      Baur X, Posch A. Characterized allergens causing bakers' asthma. Allergy 1998; 53:562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/55/38776/abstract/32\">",
"      Quirce S, Polo F, Figueredo E, et al. Occupational asthma caused by soybean flour in bakers--differences with soybean-induced epidemic asthma. Clin Exp Allergy 2000; 30:839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/55/38776/abstract/33\">",
"      Escudero C, Quirce S, Fern&aacute;ndez-Nieto M, et al. Egg white proteins as inhalant allergens associated with baker's asthma. Allergy 2003; 58:616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/55/38776/abstract/34\">",
"      Bernstein DI, Smith AB, Moller DR, et al. Clinical and immunologic studies among egg-processing workers with occupational asthma. J Allergy Clin Immunol 1987; 80:791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/55/38776/abstract/35\">",
"      van der Walt A, Lopata AL, Nieuwenhuizen NE, Jeebhay MF. Work-related allergy and asthma in spice mill workers - The impact of processing dried spices on IgE reactivity patterns. Int Arch Allergy Immunol 2010; 152:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/55/38776/abstract/36\">",
"      Kim JH, Choi GS, Kim JE, et al. Three cases of rice-induced occupational asthma. Ann Allergy Asthma Immunol 2010; 104:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/55/38776/abstract/37\">",
"      Pascual CY, Reche M, Fiandor A, et al. Fish allergy in childhood. Pediatr Allergy Immunol 2008; 19:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/55/38776/abstract/38\">",
"      Taylor AV, Swanson MC, Jones RT, et al. Detection and quantitation of raw fish aeroallergens from an open-air fish market. J Allergy Clin Immunol 2000; 105:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/55/38776/abstract/39\">",
"      Kalogeromitros D, Makris M, Gregoriou S, et al. IgE-mediated sensitization in seafood processing workers. Allergy Asthma Proc 2006; 27:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/55/38776/abstract/40\">",
"      Burks AW, James JM, Hiegel A, et al. Atopic dermatitis and food hypersensitivity reactions. J Pediatr 1998; 132:132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/55/38776/abstract/41\">",
"      Sampson HA, McCaskill CC. Food hypersensitivity and atopic dermatitis: evaluation of 113 patients. J Pediatr 1985; 107:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/55/38776/abstract/42\">",
"      Gangur V, Kelly C, Navuluri L. Sesame allergy: a growing food allergy of global proportions? Ann Allergy Asthma Immunol 2005; 95:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/55/38776/abstract/43\">",
"      Keskin O, Sekerel BE. Poppy seed allergy: a case report and review of the literature. Allergy Asthma Proc 2006; 27:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/55/38776/abstract/44\">",
"      Palma-Carlos AG, Palma-Carlos ML, Tengarrinha F. Allergy to sunflower seeds. Eur Ann Allergy Clin Immunol 2005; 37:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/55/38776/abstract/45\">",
"      James JM. Anaphylactic reactions to foods. Immunol Allergy Clin N Am 2001; 21:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/55/38776/abstract/46\">",
"      James JM, Crespo JF. Allergic reactions to foods by inhalation. Curr Allergy Asthma Rep 2007; 7:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/55/38776/abstract/47\">",
"      Brant A. Baker's asthma. Curr Opin Allergy Clin Immunol 2007; 7:152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/55/38776/abstract/48\">",
"      Moreno-Ancillo A, Gil-Adrados AC, Cosmes PM, et al. Role of Dau c 1 in three different patterns of carrot-induced asthma. Allergol Immunopathol (Madr) 2006; 34:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/55/38776/abstract/49\">",
"      Crespo JF, Rodr&iacute;guez J, Vives R, et al. Occupational IgE-mediated allergy after exposure to lupine seed flour. J Allergy Clin Immunol 2001; 108:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/55/38776/abstract/50\">",
"      Moreno-Ancillo A, Gil-Adrados AC, Dom&iacute;nguez-Noche C, Cosmes PM. Lupine inhalation induced asthma in a child. Pediatr Allergy Immunol 2005; 16:542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/55/38776/abstract/51\">",
"      Tabar AI, Alvarez-Puebla MJ, Gomez B, et al. Diversity of asparagus allergy: clinical and immunological features. Clin Exp Allergy 2004; 34:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/55/38776/abstract/52\">",
"      Rodrigo MJ, Cruz MJ, Garc&iacute;a MD, et al. Epidemic asthma in Barcelona: an evaluation of new strategies for the control of soybean dust emission. Int Arch Allergy Immunol 2004; 134:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/55/38776/abstract/53\">",
"      James JM, Bernhisel-Broadbent J, Sampson HA. Respiratory reactions provoked by double-blind food challenges in children. Am J Respir Crit Care Med 1994; 149:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/55/38776/abstract/54\">",
"      Pinnock CB, Graham NM, Mylvaganam A, Douglas RM. Relationship between milk intake and mucus production in adult volunteers challenged with rhinovirus-2. Am Rev Respir Dis 1990; 141:352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/55/38776/abstract/55\">",
"      Nsouli TM, Nsouli SM, Linde RE, et al. Role of food allergy in serous otitis media. Ann Allergy 1994; 73:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/55/38776/abstract/56\">",
"      Bernstein JM. The role of IgE-mediated hypersensitivity in the development of otitis media with effusion: a review. Otolaryngol Head Neck Surg 1993; 109:611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/55/38776/abstract/57\">",
"      Practice parameters for the diagnosis and treatment of asthma. Joint Task Force on Practice Parameters, representing the American Academy of Allergy Asthma and Immunology, the American College of Allergy, Asthma and Immunology, and the Joint Council of Allergy, Asthma and Immunology. J Allergy Clin Immunol 1995; 96:707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/55/38776/abstract/58\">",
"      Malo JL, Chan-Yeung M. Agents causing occupational asthma. J Allergy Clin Immunol 2009; 123:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/55/38776/abstract/59\">",
"      Dykewicz MS. Occupational asthma: current concepts in pathogenesis, diagnosis, and management. J Allergy Clin Immunol 2009; 123:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/55/38776/abstract/60\">",
"      Novembre E, de Martino M, Vierucci A. Foods and respiratory allergy. J Allergy Clin Immunol 1988; 81:1059.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/55/38776/abstract/61\">",
"      Oehling A, Baena Cagnani CE. Food allergy and child asthma. Allergol Immunopathol (Madr) 1980; 8:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/55/38776/abstract/62\">",
"      Yazicio��lu M, Ba��pinar I, One�� U, et al. Egg and milk allergy in asthmatic children: assessment by immulite allergy food panel, skin prick tests and double-blind placebo-controlled food challenges. Allergol Immunopathol (Madr) 1999; 27:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/55/38776/abstract/63\">",
"      Ranc&eacute; F, Dutau G. [Asthma and food allergy: report of 163 pediatric cases]. Arch Pediatr 2002; 9 Suppl 3:402s.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/55/38776/abstract/64\">",
"      Bock SA. Respiratory reactions induced by food challenges in children with pulmonary disease. Pediatr Allergy Immunol 1992; 3:188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/55/38776/abstract/65\">",
"      Businco L, Falconieri P, Giampietro P, Bellioni B. Food allergy and asthma. Pediatr Pulmonol Suppl 1995; 11:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/55/38776/abstract/66\">",
"      Hill DJ, Firer MA, Shelton MJ, Hosking CS. Manifestations of milk allergy in infancy: clinical and immunologic findings. J Pediatr 1986; 109:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/55/38776/abstract/67\">",
"      Pavlovic M, Spasojevic M, Tasic Z, Tacevic S. Bronchial hyperactivity in bakers and its relation to atopy and skin reactivity. Sci Total Environ 2001; 270:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/55/38776/abstract/68\">",
"      James JM, Eigenmann PA, Eggleston PA, Sampson HA. Airway reactivity changes in asthmatic patients undergoing blinded food challenges. Am J Respir Crit Care Med 1996; 153:597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/55/38776/abstract/69\">",
"      Zwetchkenbaum JF, Skufca R, Nelson HS. An examination of food hypersensitivity as a cause of increased bronchial responsiveness to inhaled methacholine. J Allergy Clin Immunol 1991; 88:360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/55/38776/abstract/70\">",
"      Thaminy A, Lamblin C, Perez T, et al. Increased frequency of asymptomatic bronchial hyperresponsiveness in nonasthmatic patients with food allergy. Eur Respir J 2000; 16:1091.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/55/38776/abstract/71\">",
"      Kivity S, Fireman E, Sade K. Bronchial hyperactivity, sputum analysis and skin prick test to inhalant allergens in patients with symptomatic food hypersensitivity. Isr Med Assoc J 2005; 7:781.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2412 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-60.18.131.125-92069A6D88-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_55_38776=[""].join("\n");
var outline_f37_55_38776=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Prevalence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      ASSOCIATIONS BETWEEN FOOD ALLERGY AND ASTHMA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Atopic march",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Marker for asthma severity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Marker for fatal anaphylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Routes of exposure",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Ingestion",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Inhalation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Allergens",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      RESPIRATORY MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Upper respiratory symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Asthma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Baker's asthma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Airway hyperresponsiveness",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Anaphylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/46/40681?source=related_link\">",
"      Allergic and asthmatic reactions to food additives",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/52/11082?source=related_link\">",
"      Clinical manifestations and diagnosis of oral allergy syndrome (pollen-food allergy syndrome)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/29/14808?source=related_link\">",
"      Clinical manifestations of food allergy: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/12/5321?source=related_link\">",
"      Diagnostic evaluation of food allergy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/13/1241?source=related_link\">",
"      Fatal anaphylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/0/38920?source=related_link\">",
"      Food-induced anaphylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/17/26904?source=related_link\">",
"      History and physical examination in the patient with possible food allergy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/48/18185?source=related_link\">",
"      Management of food allergy: Avoidance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/15/36089?source=related_link\">",
"      Occupational asthma: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/0/34824?source=related_link\">",
"      Occupational asthma: Definitions, epidemiology, causes, and risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/48/7945?source=related_link\">",
"      Occupational rhinitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/59/20409?source=related_link\">",
"      Oral food challenges for diagnosis and management of food allergies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/42/43689?source=related_link\">",
"      Pathogenesis of food allergy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?28/47/29429?source=related_link\">",
"      Patient information: Food allergy symptoms and diagnosis (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_55_38777="Mycobacterium avium complex (MAC) infections in HIV-infected patients";
var content_f37_55_38777=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Mycobacterium avium complex (MAC) infections in HIV-infected patients",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/55/38777/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/55/38777/contributors\">",
"     Judith S Currier, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/55/38777/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/55/38777/contributors\">",
"     John G Bartlett, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/55/38777/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/55/38777/contributors\">",
"     Allyson Bloom, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?37/55/38777/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 28, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mycobacterium avium complex (MAC) refers to infections caused by one of two nontuberculous mycobacterial species, either M. avium or M. intracellulare. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/35/5687?source=see_link\">",
"     \"Microbiology of nontuberculous mycobacteria\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    While infections with these organisms can occur in patients who are not HIV-infected, the frequency of infection increased and the nomenclature MAC was developed early in the HIV epidemic. Dramatic declines in the rate of new MAC cases in HIV-infected patients have accompanied the use of more effective antiretroviral therapy (ART) and the more widespread use of prophylaxis against MAC infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/55/38777/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/42/33450?source=see_link\">",
"     \"Primary prevention of opportunistic infections in HIV-infected patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/33/24089?source=see_link\">",
"     \"Epidemiology of nontuberculous mycobacterial infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The epidemiology and clinical manifestations of MAC infection and current knowledge about the prevention and therapy of MAC in HIV disease will be reviewed here. MAC infections in patients without HIV are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/11/24759?source=see_link\">",
"     \"Overview of nontuberculous mycobacterial infections in HIV-negative patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/24/2441?source=see_link\">",
"     \"Treatment of nontuberculous mycobacterial infections of the lung in HIV-negative patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Transmission",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mycobacterium avium complex organisms are ubiquitous in the environment, including water and soil [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/55/38777/abstract/4\">",
"     4",
"    </a>",
"    ]. The mode of infection for MAC infection is thought to be through inhalation or ingestion.",
"   </p>",
"   <p>",
"    Person-to-person or common source transmission of MAC does not appear to be common; there is no need for isolation of hospitalized patients with MAC infection.",
"   </p>",
"   <p>",
"    In one report of 32 AIDS patients with MAC from a daycare center in France over a 13-month period, the strains of organisms were heterogeneous by pulsed-field gel electrophoresis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/55/38777/abstract/5\">",
"     5",
"    </a>",
"    ]. Another series of 130 isolates from children, both HIV-infected and not infected, also failed to show a clonal origin for the strains although HIV-infected children were more commonly infected with M. avium than controls (88 versus 38 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/55/38777/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of MAC in patients with HIV infection increases as the CD4 cell number declines below 50",
"    <span class=\"nowrap\">",
"     cells/mm3.",
"    </span>",
"    The risk does not appear to vary by gender, ethnicity, or route of transmission. In one study, rates of MAC disease were higher in the southern than in the northern United States and Canada (22 versus 14 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/55/38777/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    MAC infection has been reported to be more common in HIV-infected patients in the United States than in Europe [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/55/38777/abstract/8\">",
"     8",
"    </a>",
"    ]. One international study found significantly higher rates of disseminated MAC in developed compared to developing countries (10 to 22 percent versus 2 to 3 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/55/38777/abstract/9\">",
"     9",
"    </a>",
"    ]. From this same study, risk factors for disseminated disease in the United States and Finland included:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Low CD4 count",
"     </li>",
"     <li>",
"      Use of an indoor pool for swimming",
"     </li>",
"     <li>",
"      Previous bronchoscopy",
"     </li>",
"     <li>",
"      Repeated consumption of raw or partially cooked fish or shellfish",
"     </li>",
"     <li>",
"      Therapy with granulocyte stimulating factor.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Host genetics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Finally, patients with disseminated MAC may also have a genetic predisposition to infection. In a nested case control study from the Multicenter AIDS Cohort (MACS), specific HLA class II alleles (DRB1, DQB, DM) were more commonly found in association with disease (176 cases) compared to matched controls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/55/38777/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unlike some other OIs in AIDS, MAC is thought to represent recent acquisition rather than reactivation since latent infection does not exist with this organism. The portals of entry for the organism appear to be the respiratory and gastrointestinal tract with bacteremia following dissemination via the lymphatics.",
"   </p>",
"   <p>",
"    Virulence factors for MAC have not been established. One study has suggested that differential virulence among strains, as assessed by cell invasion or macrophage replication assays, varies among colonizing strains as compared to those associated with disseminated disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/55/38777/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The mechanisms of interaction among MAC, HIV-1 virus, and the immune system are also incompletely understood. In one study tumor necrosis factor (TNF) alpha levels were increased and the HIV macrophage-tropic receptor, CCR5, was upregulated by monocytes exposed in vitro to MAC organisms or antigens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/55/38777/abstract/12\">",
"     12",
"    </a>",
"    ]. The expression of the T cell-tropic receptor, CXCR4, was not affected. HIV-1 production was also increased in macrophage tissue culture cells previously exposed to MAC antigens. In lymph node tissue co-infected with MAC and HIV-1, increased levels of CCR5 were demonstrated in comparison to lymph nodes infected with HIV-1 alone.",
"   </p>",
"   <p>",
"    Receipt of granulocyte stimulating factor was identified as a possible epidemiologic risk factor for disseminated MAC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/55/38777/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Epidemiology'",
"    </a>",
"    above.) However, in one in vitro study, neutrophils harvested from AIDS patients treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/13/23767?source=see_link\">",
"     granulocyte colony-stimulating factor",
"    </a>",
"    (G-CSF) produced enhanced killing of M. avium compared to cells from patients treated with G-CSF plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/63/32760?source=see_link\">",
"     rifabutin",
"    </a>",
"    or rifabutin alone (90 versus 59 and 11 percent, respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/55/38777/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The two principal forms of MAC infection in HIV are disseminated and localized disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/55/38777/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Disseminated infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, in the era before the availability of highly active antiretroviral therapy (HAART), MAC most commonly presented as disseminated disease. A prospective study documented that colonization of the respiratory and gastrointestinal tract had a low sensitivity (approximately 20 percent) but a good positive predictive value (60 percent) for detecting disseminated disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/55/38777/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The most common symptoms of disseminated MAC are non-specific and include: fever, night sweats, abdominal pain, diarrhea, and weight loss (which often precedes the onset of fever). In one series of 9 patients, fever &ge;39&ordm; C was found in 78 percent, weight loss in 100 percent, cough in 78 percent, and diarrhea in 44 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/55/38777/abstract/16\">",
"     16",
"    </a>",
"    ]. Laboratory abnormalities frequently include anemia and elevated alkaline phosphatase and lactate dehydrogenase. The diagnosis is confirmed by the isolation of MAC from the blood. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Localized disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;In immunocompetent adults and children, focal lymphadenitis is a common presentation of nontuberculous mycobacterial disease. In patients with HIV infection, localized disease was uncommon prior to the HAART era. Several series have described patients with HIV infection who have developed a focal inflammatory lymphadenitis shortly after the initiation of HAART [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/55/38777/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. In all of these cases the patients had a prior history of a low CD4 cell number that may have predisposed them to colonization with MAC.",
"   </p>",
"   <p>",
"    The symptoms of localized disease have included fever, leukocytosis, and focal inflammation in a lymph node (cervical, intraabdominal, mediastinal). Blood cultures have almost always been sterile. The diagnosis is confirmed by culture of an aspirate of the lymph node. Antimycobacterial therapy combined with corticosteroids in cases with a prominent inflammatory component has been successful in anecdotal case reports. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The focal nature of this presentation has led several authors to conclude that the restoration of immune function during HAART has unmasked a previously subclinical tissue infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/55/38777/abstract/17,19\">",
"     17,19",
"    </a>",
"    ]. Two cases of spinal MAC have been described in patients with a more prolonged response to antiretroviral therapy after having a nadir CD4 count &lt;50",
"    <span class=\"nowrap\">",
"     cell/mm3",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/55/38777/abstract/18\">",
"     18",
"    </a>",
"    ]. Other unusual presentations have included mastitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/55/38777/abstract/20\">",
"     20",
"    </a>",
"    ]. Clinicians need to be aware of unusual presentations of MAC in the era of more potent antiretroviral therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Effect on HIV infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The consequence of MAC infection on HIV disease have also been explored. A case-control study also found a small but significant increase in HIV RNA levels in patients with MAC bacteremia compared to controls from the pre-HAART era [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/55/38777/abstract/21\">",
"     21",
"    </a>",
"    ]. A mean increase of 0.4 log 10",
"    <span class=\"nowrap\">",
"     copies/mL",
"    </span>",
"    was documented in cases compared to control AIDS patients matched for CD4 counts, prophylaxis against MAC, antiretroviral treatment, and duration of follow-up.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, the diagnosis of MAC is made by isolation of the organism in culture usually of the blood or lymph node. When the BACTEC culture system is used, the cultures usually become positive in 7 to 10 days. Species identification using DNA probes distinguishes MAC from M. tuberculosis.",
"   </p>",
"   <p>",
"    Bone marrow culture often yields the organism before blood cultures turn positive, but due to the less invasive nature, blood cultures are usually the preferred initial diagnostic test. In one retrospective study the mean time to report of a positive culture of MAC from the bone marrow (22 days) was only marginally better than the time for the results of a single lysis centrifugation blood culture (24 days) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/55/38777/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    By contrast, another series compared blood cultures to bone marrow aspirate cultures or bone marrow biopsy staining for acid-fast bacilli (AFB) and found blood cultures to be the most sensitive test and to yield a more rapid diagnosis than bone marrow cultures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/55/38777/abstract/23\">",
"     23",
"    </a>",
"    ]. Of the 30 patients with disseminated MAC infection, all had positive blood cultures compared to 17 positive cultures from bone marrow aspirates and 9 positive AFB stains. Although AFB staining was the least sensitive method, results were available in a mean of 1.1 days compared to 16 and 19 days, respectively, for blood cultures and bone marrow cultures.",
"   </p>",
"   <p>",
"    Abdominal computed tomography (CT) had been advocated in the diagnostic evaluation of disseminated MAC, especially to look for lymphadenopathy. However, one retrospective study of 24 AIDS patients with positive blood cultures for MAC found this test to be relatively insensitive [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/55/38777/abstract/24\">",
"     24",
"    </a>",
"    ]. Lymphadenopathy was found less frequently than expected (42 percent compared to 50 and 46 percent for hepatomegaly and splenomegaly, respectively). Thickening of the small bowel wall was observed on 14 percent of the scans. Most notably, the CT was normal in 25 percent of the patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     PREVENTION OF MAC DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;In placebo-controlled trials,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/63/32760?source=see_link\">",
"     rifabutin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/57/10138?source=see_link\">",
"     clarithromycin",
"    </a>",
"    (a macrolide), and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    (an azalide) have each been shown to be effective in reducing the incidence of MAC and reducing mortality in patients with HIV infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/55/38777/abstract/25-28\">",
"     25-28",
"    </a>",
"    ]. The major findings from one of these trials are highlighted below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6974560\">",
"    <span class=\"h2\">",
"     Clarithromycin versus placebo",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a clinical trial, 667 AIDS patients with a CD4 count &lt;100",
"    <span class=\"nowrap\">",
"     cells/mm3",
"    </span>",
"    were randomly assigned to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/57/10138?source=see_link\">",
"     clarithromycin",
"    </a>",
"    or placebo for the prevention of Mycobacterium avium complex infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/55/38777/abstract/25\">",
"     25",
"    </a>",
"    ]. After the interim analysis, the Data Safety Monitoring Board advised that the trial be stopped due to the following results:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      M. avium complex infections developed in significantly more patients in the placebo arm (53 of 334 patients; 16 percent) compared with the intervention arm (19 of 333; 6 percent).",
"     </li>",
"     <li>",
"      Mortality rates were higher in the placebo than the intervention arm (41 versus 32 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/57/10138?source=see_link\">",
"     Clarithromycin",
"    </a>",
"    recipients had a higher incidence of taste perversion and gastrointestinal symptoms than the placebo arm; the incidence of severe adverse events was similar between the two arms (6 and 7 percent, respectively).",
"   </p>",
"   <p>",
"    Once the clinical benefit of MAC prophylaxis was recognized, subsequent clinical trials were designed to determine which prophylaxis was optimal. Comparative trials of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    versus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/63/32760?source=see_link\">",
"     rifabutin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/57/10138?source=see_link\">",
"     clarithromycin",
"    </a>",
"    versus rifabutin are discussed below. No clinical trials were performed comparing azithromycin with clarithromycin.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Azithromycin comparative trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;The California Collaborative Treatment Group (CCTG) Study 574 was a randomized, placebo controlled, trial comparing once weekly",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    (1200 mg) to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/63/32760?source=see_link\">",
"     rifabutin",
"    </a>",
"    (300",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    and to the combination of azithromycin (weekly) and rifabutin (daily) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/55/38777/abstract/29\">",
"     29",
"    </a>",
"    ]. All patients had CD4 counts less than 100",
"    <span class=\"nowrap\">",
"     cells/mm3",
"    </span>",
"    and had monthly blood cultures for MAC. The median CD4 count of the 693 randomized patients was 38",
"    <span class=\"nowrap\">",
"     cells/mm3",
"    </span>",
"    for the rifabutin group, 36",
"    <span class=\"nowrap\">",
"     cells/mm3",
"    </span>",
"    for the azithromycin group, and 45",
"    <span class=\"nowrap\">",
"     cells/mm3",
"    </span>",
"    for the combination therapy group.",
"   </p>",
"   <p>",
"    In the intent-to-treat analysis, the one-year cumulative incidence of disseminated MAC was highest in the group receiving",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/63/32760?source=see_link\">",
"     rifabutin",
"    </a>",
"    alone (15.3 versus 7.6 and 2.8 percent, respectively for the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    and the combination therapy groups). After adjustment for CD4 counts, the risk of MAC was 72 percent lower with combination therapy than with rifabutin alone, and 47 percent lower than with azithromycin alone. The risk of MAC in patients taking azithromycin was 47 percent lower than the risk in patients taking rifabutin.",
"   </p>",
"   <p>",
"    An additional benefit of the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    -containing prophylaxis regimen was observed in the primary prevention of Pneumocystis carinii pneumonia (PCP). Patients receiving azithromycin alone or in combination with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/63/32760?source=see_link\">",
"     rifabutin",
"    </a>",
"    had a 45 percent reduction in the risk of developing a first episode of PCP [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/55/38777/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/43/33456?source=see_link\">",
"     Azithromycin",
"    </a>",
"    (and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/57/10138?source=see_link\">",
"     clarithromycin",
"    </a>",
"    minimum inhibitory concentration (MIC) &gt;16",
"    <span class=\"nowrap\">",
"     microgram/mL)",
"    </span>",
"    resistant MAC was identified in 2 of 18 breakthrough isolates (11 percent) on azithromycin and in none in the combination arm. No",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/63/32760?source=see_link\">",
"     rifabutin",
"    </a>",
"    resistant isolates were identified. Dose limiting toxicity was highest in the combination arm (21 percent), which was statistically significant compared to the groups receiving either drug alone.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Clarithromycin comparative trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ACTG",
"    <span class=\"nowrap\">",
"     196/CPCRA",
"    </span>",
"    009 study compared",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/57/10138?source=see_link\">",
"     clarithromycin",
"    </a>",
"    (500 mg twice daily) to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/63/32760?source=see_link\">",
"     rifabutin",
"    </a>",
"    (300 mg daily) and to the combination of clarithromycin (500 mg twice daily) and rifabutin (300 mg daily) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/55/38777/abstract/31\">",
"     31",
"    </a>",
"    ]. All patients had CD4 counts less than 100",
"    <span class=\"nowrap\">",
"     cells/mm3",
"    </span>",
"    and in contrast to the CCTG study had blood cultures obtained only every two months. The median CD4 count of the 1178 eligible patients at entry was 27",
"    <span class=\"nowrap\">",
"     cells/mm3.",
"    </span>",
"   </p>",
"   <p>",
"    The",
"    cumulative incidence of disseminated MAC at one year in the intent-to-treat analysis was also highest for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/63/32760?source=see_link\">",
"     rifabutin",
"    </a>",
"    in this study although the combination of the drugs offered no increased protection compared to the macrolide arm alone (10 versus 5 percent for both the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/57/10138?source=see_link\">",
"     clarithromycin",
"    </a>",
"    group and the drug combination group). Treatment-limiting toxicity was highest in the combination arm (31 versus 16 and 18 percent for the clarithromycin and rifabutin arms, respectively).",
"   </p>",
"   <p>",
"    Susceptibility testing identified",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/57/10138?source=see_link\">",
"     clarithromycin",
"    </a>",
"    -resistant MAC (MIC &gt;32",
"    <span class=\"nowrap\">",
"     microgram/mL)",
"    </span>",
"    in 29 percent of the clarithromycin failures and 25 percent of the breakthroughs in the combination arm.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/63/32760?source=see_link\">",
"     Rifabutin",
"    </a>",
"    resistance (MIC &gt;2.0",
"    <span class=\"nowrap\">",
"     microgram/mL)",
"    </span>",
"    was identified in two isolates, one from a patient receiving rifabutin and one from a patient receiving clarithromycin.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Recommended drug choice",
"    </span>",
"    &nbsp;&mdash;&nbsp;The data from these studies demonstrate that both daily",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/57/10138?source=see_link\">",
"     clarithromycin",
"    </a>",
"    and once weekly",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    are superior to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/63/32760?source=see_link\">",
"     rifabutin",
"    </a>",
"    for MAC prophylaxis. Combination therapy with rifabutin and clarithromycin adds only toxicity and cost and does not improve efficacy or reduce the risk of macrolide resistance. Combining rifabutin with azithromycin appears to increase efficacy but with added toxicity. While there is no head-to-head comparison of azithromycin and clarithromycin, many clinicians favor azithromycin based upon the once weekly dosing and fewer drug interactions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Timing of the initiation of prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Current",
"    <span class=\"nowrap\">",
"     USPHS/IDSA",
"    </span>",
"    guidelines recommend that MAC prophylaxis should be initiated in patients with a current CD4 count of less than 50",
"    <span class=\"nowrap\">",
"     cells/mm3",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/55/38777/abstract/27,32\">",
"     27,32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Data indicate that CD4 cell increases produced on antiretroviral therapy are associated with a reduction in the risk of subsequent OIs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/55/38777/abstract/33-38\">",
"     33-38",
"    </a>",
"    ]. Data have emerged to suggest that it may take three to six months after starting antiretroviral therapy before immune function is restored to a level that would reduce the risk of MAC (and other OIs) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/55/38777/abstract/39\">",
"     39",
"    </a>",
"    ]. Factors that may contribute to the future risk of MAC include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The pre-therapy viral load",
"     </li>",
"     <li>",
"      History of prior OIs",
"     </li>",
"     <li>",
"      The magnitude of the CD4 increase on therapy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6554371\">",
"    <span class=\"h2\">",
"     Discontinuation of prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The results of two randomized clinical trials investigating the safety of discontinuing prophylaxis for MAC form the basis of current recommendations. The first trial, ACTG 362, randomized 643 HIV infected subjects, whose CD4 counts rose from less than",
"    <span class=\"nowrap\">",
"     50/microL",
"    </span>",
"    to above 100, to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    (1200 mg once per week) or placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/55/38777/abstract/18\">",
"     18",
"    </a>",
"    ]. After a median follow-up of 16 months, two cases of MAC disease localized to the spine developed in the placebo group compared to no cases in those randomized to azithromycin. The overall MAC infection rate in the placebo arm was lower than the rate previously observed in patients on sustained",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/63/32760?source=see_link\">",
"     rifabutin",
"    </a>",
"    , azithromycin, or combined prophylaxis (0.5 events per100 person-years versus 15.3, 7.6, and 2.8, respectively).",
"   </p>",
"   <p>",
"    The second study was randomized, multicenter, double-blind trial compared continuing or stopping",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    prophylaxis in AIDS patients whose CD4 counts had risen to",
"    <span class=\"nowrap\">",
"     &gt;100/microL",
"    </span>",
"    on two consecutive determinations in response to HAART therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/55/38777/abstract/40\">",
"     40",
"    </a>",
"    ]. The 520 randomized patients had a median of 23 CD4",
"    <span class=\"nowrap\">",
"     cells/microL",
"    </span>",
"    at the lowest point and",
"    <span class=\"nowrap\">",
"     230/microL",
"    </span>",
"    upon enrollment; 50 percent had viral loads &lt;400",
"    <span class=\"nowrap\">",
"     copies/mL,",
"    </span>",
"    which was undetectable by the assay employed. During an median of 12 months of follow-up, no patients in either group developed MAC infection and the incidence of bacterial pneumonia, progression of HIV, and death also did not differ.",
"   </p>",
"   <p>",
"    These two clinical trials support the 2009 recommendations of the",
"    <span class=\"nowrap\">",
"     USPHS/IDSA",
"    </span>",
"    to discontinue MAC prophylaxis three months after patients attain a CD4 cell count &gt;100",
"    <span class=\"nowrap\">",
"     cells/mm3",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/55/38777/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     MORTALITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is well established that MAC disease is associated with a shortened survival in AIDS. In one study a diagnosis of MAC was associated with a threefold increased risk of death, independent of CD4 count [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/55/38777/abstract/41\">",
"     41",
"    </a>",
"    ]. The increased mortality may be explained by upregulation of HIV RNA or by direct effects of MAC infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/55/38777/abstract/21\">",
"     21",
"    </a>",
"    ]. For this reason, therapy for MAC is indicated in HIV infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     THERAPY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     General principles",
"    </span>",
"    &nbsp;&mdash;&nbsp;Combination drug therapy is necessary to decrease the risk of drug resistance. Treatment with more than one agent is also associated with more rapid clearance of MAC from the bloodstream [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/55/38777/abstract/42\">",
"     42",
"    </a>",
"    ]. Agents with MAC activity include",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/57/10138?source=see_link\">",
"     clarithromycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/7/12406?source=see_link\">",
"     ethambutol",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/63/32760?source=see_link\">",
"     rifabutin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/16/34056?source=see_link\">",
"     amikacin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/9/18583?source=see_link\">",
"     streptomycin",
"    </a>",
"    , and fluoroquinolones.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     First-line agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/57/10138?source=see_link\">",
"     Clarithromycin",
"    </a>",
"    (500 mg PO BID) and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    (600 mg once daily) are the cornerstones of therapy.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/57/10138?source=see_link\">",
"     Clarithromycin",
"    </a>",
"    is the preferred first agent due to more extensive study in AIDS patients with MAC infection. One study directly compared clarithromycin plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/7/12406?source=see_link\">",
"     ethambutol",
"    </a>",
"    to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    (600 mg PO once daily) plus ethambutol and was stopped based upon an interim analysis that showed that the clarithromycin-containing regimen was superior [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/55/38777/abstract/43\">",
"     43",
"    </a>",
"    ]. Of 37 evaluable AIDS patients with MAC bacteremia, the organism was eliminated from the bloodstream in 86 percent of the patients receiving the clarithromycin regimen compared to only 38 percent for the azithromycin regimen; the median time to clearance was also significantly shorter for the clarithromycin group (4.4 versus &gt;16 weeks).",
"   </p>",
"   <p>",
"    However,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    can be substituted if the patient is having difficulty with tolerance of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/57/10138?source=see_link\">",
"     clarithromycin",
"    </a>",
"    or if there are concerns regarding drug interactions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/55/38777/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Second-line agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;The candidate second agents include",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/7/12406?source=see_link\">",
"     ethambutol",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/63/32760?source=see_link\">",
"     rifabutin",
"    </a>",
"    . However, the results of four randomized trials of MAC therapy in AIDS (",
"    <a class=\"graphic graphic_table graphicRef65168 \" href=\"mobipreview.htm?26/46/27371\">",
"     table 1",
"    </a>",
"    ) demonstrate that ethambutol (15",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    PO once daily) is associated with lower rates of relapse in two studies and is the preferred second agent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/55/38777/abstract/44-47\">",
"     44-47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is a bidirectional drug interaction between",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/57/10138?source=see_link\">",
"     clarithromycin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/63/32760?source=see_link\">",
"     rifabutin",
"    </a>",
"    , with increased levels of rifabutin and decreased levels of clarithromycin and increases in the major metabolite 14-OH clarithromycin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/55/38777/abstract/48\">",
"     48",
"    </a>",
"    ]. Uveitis occurred in a substantial proportion of patients when rifabutin (600 mg daily) was combined with clarithromycin in one study; in addition to the dose, lower body weight also was associated with an increased risk of uveitis. The risk of uveitis is markedly decreased when a dose of 300 mg daily of rifabutin is used [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/55/38777/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is evidence suggesting that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/63/32760?source=see_link\">",
"     rifabutin",
"    </a>",
"    may add to the efficacy of the combination of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/57/10138?source=see_link\">",
"     clarithromycin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/7/12406?source=see_link\">",
"     ethambutol",
"    </a>",
"    for the treatment of MAC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/55/38777/abstract/42\">",
"     42",
"    </a>",
"    ]. AIDS Clinical Trials Group Study 223 compared three clarithromycin containing regimens for the treatment of disseminated MAC. Mycobacteremic patients were randomized to open label therapy with clarithromycin plus ethambutol (15",
"    <span class=\"nowrap\">",
"     mg/kg/day),",
"    </span>",
"    clarithromycin plus rifabutin (450 mg once daily), or the three-drug combination of clarithromycin, ethambutol, and rifabutin. The dose of rifabutin was decreased from 450",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    to 150 mg once daily for patients receiving a protease inhibitor (150 mg every other day with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/58/12202?source=see_link\">",
"     ritonavir",
"    </a>",
"    ). The rates of complete microbiologic response were the same in all three treatment groups at 12 weeks (40 percent for C+E, 42 percent C+R, and 51 percent for C+R+E). Patients assigned to the three drug combination were less likely to relapse than those on two drug combination of clarithromycin and rifabutin and most importantly had an increased survival compared to each of the two drug therapy groups (p&lt;0.05).",
"   </p>",
"   <p>",
"    This study demonstrates a benefit from the addition of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/63/32760?source=see_link\">",
"     rifabutin",
"    </a>",
"    to the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/57/10138?source=see_link\">",
"     clarithromycin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/7/12406?source=see_link\">",
"     ethambutol",
"    </a>",
"    for first line therapy for MAC. It is important to recognize that this study was conducted during a time period that spans the introduction of protease inhibitors and the use of a protease inhibitor (35 percent of subjects reported use prior to or during the study) was also associated with improved survival. After control for protease inhibitor use the survival benefit from the three drug arm persisted [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/55/38777/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Currently, we prefer to start with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/57/10138?source=see_link\">",
"     clarithromycin",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/7/12406?source=see_link\">",
"     ethambutol",
"    </a>",
"    and add",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/63/32760?source=see_link\">",
"     rifabutin",
"    </a>",
"    if the patient is not yet on a protease inhibitor. Concurrent use of rifabutin and a protease inhibitor can be considered, however, the dose of rifabutin needs to be reduced [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/55/38777/abstract/50\">",
"     50",
"    </a>",
"    ]. Rifabutin may have important drug interactions with other antiretroviral agents, so caution should be used when considering the addition of rifabutin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/55/38777/abstract/51\">",
"     51",
"    </a>",
"    ]. Therapy should be continued for at least 12 months. The decision to discontinue MAC therapy after one year in patients who have responded to HAART is discussed below (see",
"    <a class=\"local\" href=\"#H28\">",
"     'Safety of discontinuing MAC therapy'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    Clofazimine should be avoided; in one study of 106 AIDS patients with MAC bacteremia randomized to treatment with a two- (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/57/10138?source=see_link\">",
"     clarithromycin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/7/12406?source=see_link\">",
"     ethambutol",
"    </a>",
"    ) or three- (the same two drugs plus clofazimine) drug regimen, the clofazimine regimen was associated with a higher mortality rate (61 versus 38 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/55/38777/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Addition of third agent",
"    </span>",
"    &nbsp;&mdash;&nbsp;Additional medications (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/16/34056?source=see_link\">",
"     amikacin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/9/18583?source=see_link\">",
"     streptomycin",
"    </a>",
"    ) should be considered in the patient with advanced immunosuppression (eg, CD4 cell count &le;50",
"    <span class=\"nowrap\">",
"     cells/mm3),",
"    </span>",
"    high mycobacterial loads (&gt;2 log(20) colony forming",
"    <span class=\"nowrap\">",
"     units/mL",
"    </span>",
"    of blood) or in the absence of effective ART.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Addition of antiretroviral therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;If a patient is on ART at the time of diagnosis, ART should be continued and optimized if viremia is not suppressed. If a patient is treatment-naive or is not currently taking ART, the CDC treatment guidelines recommend initiation of ART after two weeks of MAC therapy to decrease the risk of complications associated with IRIS and overlapping drug toxicities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/55/38777/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Adjunctive therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adjunctive therapy with immunomodulatory agents has not been thoroughly studied and is not recommended [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/55/38777/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Monitoring of therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Improvement in the fever curve and a decline in quantity of mycobacteria in the bloodstream should be seen in two to four weeks after initiation of therapy. If no clinical improvement is seen, a repeat blood culture should be obtained to determine if the patient has ongoing mycobacteremia.",
"   </p>",
"   <p>",
"    Drug resistance testing should also be considered, particularly if the patient developed MAC disease while taking prophylaxis. However, prior studies have demonstrated",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/57/10138?source=see_link\">",
"     clarithromycin",
"    </a>",
"    sensitivity in patients who failed primary prophylaxis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/55/38777/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Potential adverse events associated with treatment of MAC infection include gastrointestinal intolerance, abnormal liver function tests related to macrolides, and optic neuritis related to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/7/12406?source=see_link\">",
"     ethambutol",
"    </a>",
"    . Patients should have baseline and monthly testing for color vision and visual acuity during ethambutol therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/2/30757?source=see_link\">",
"     \"Ethambutol: An overview\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/21/19802?source=see_link\">",
"     \"Treatment of pulmonary tuberculosis in HIV-negative patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/21/19802?source=see_link&amp;anchor=H11#H11\">",
"     \"Treatment of pulmonary tuberculosis in HIV-negative patients\", section on 'Other adverse effects'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Management of treatment failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment failure is defined by lack of clinical response in the setting on ongoing mycobacteremia. Results of susceptibility testing should be used to construct a new multidrug regimen with at least two new agents. The following medications can be considered:",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/7/12406?source=see_link\">",
"     ethambutol",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/63/32760?source=see_link\">",
"     rifabutin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/46/33504?source=see_link\">",
"     levofloxacin",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/16/34056?source=see_link\">",
"     amikacin",
"    </a>",
"    . Optimizing HAART is also an important adjunct to therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Summary recommendations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Guidelines from the CDC, NIH, HIV Medicine Association and IDSA suggest that at least two drugs should be used for the initial treatment of disseminated MAC infection to delay the emergence of resistance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/55/38777/abstract/14\">",
"     14",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/57/10138?source=see_link\">",
"       Clarithromycin",
"      </a>",
"      is the preferred first agent, since it has been studied more extensively than",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/43/33456?source=see_link\">",
"       azithromycin",
"      </a>",
"      . However azithromycin can be considered if drug interactions or clarithromycin intolerance is a consideration.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?12/7/12406?source=see_link\">",
"       Ethambutol",
"      </a>",
"      is the recommended second drug.",
"     </li>",
"     <li>",
"      Some clinicians may consider adding",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/63/32760?source=see_link\">",
"       rifabutin",
"      </a>",
"      as a third drug due to studies documenting improved survival documented prior to the era of HAART. The addition of rifabutin can be considered in the patient with high mycobacterial loads (greater than 2 log colony forming",
"      <span class=\"nowrap\">",
"       units/mL",
"      </span>",
"      of blood) or in the absence of effective HAART.",
"     </li>",
"     <li>",
"      If",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/63/32760?source=see_link\">",
"       rifabutin",
"      </a>",
"      cannot be used due to drug interactions, use of fluoroquinolones or parenteral",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/16/34056?source=see_link\">",
"       amikacin",
"      </a>",
"      can be used, although their efficacy has not been documented in clinical trials.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The new guidelines also advocate the initiation of potent combination antiretroviral therapy after one to two weeks of treatment if DMAC is diagnosed in an antiretroviral na&iuml;ve patient. Clinicians should be aware of the potential risks of immune reconstitution syndrome if HAART is initiated. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/35/23098?source=see_link\">",
"     \"Immune reconstitution inflammatory syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Safety of discontinuing MAC therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The duration of treatment for disseminated MAC in HIV-infected patients without immune reconstitution is life-long. However, several studies suggest a potential to cure MAC disease following immune reconstitution [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/55/38777/abstract/52-54\">",
"     52-54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The largest was a prospective observational cohort study assessing the discontinuation of maintenance therapy for OIs in seven European HIV cohorts; 103 patients had disseminated MAC and had been treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?12/7/12406?source=see_link\">",
"       ethambutol",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/57/10138?source=see_link\">",
"       clarithromycin",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/43/33456?source=see_link\">",
"       azithromycin",
"      </a>",
"      with or without",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/63/32760?source=see_link\">",
"       rifabutin",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/55/38777/abstract/52\">",
"       52",
"      </a>",
"      ]. Maintenance therapy for the infection was stopped at a median CD4 count of 190",
"      <span class=\"nowrap\">",
"       cells/microL",
"      </span>",
"      (range 129 to 290), and 80 percent of patients had viral loads &lt;500",
"      <span class=\"nowrap\">",
"       copies/mL",
"      </span>",
"      (range &lt;500 to 1183). Two patients relapsed for a relapse rate of 1 per 100 person-years of follow-up.",
"     </li>",
"     <li>",
"      The second study was a retrospective analysis of 52 patients who discontinued MAC therapy after viral load reduction; patients had been on MAC therapy for a median of 32 months (range 4 to 87), and follow up after cessation of treatment was for a median of 20 months (4 to 52 months) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/55/38777/abstract/53\">",
"       53",
"      </a>",
"      ]. One patient experienced relapse two months following discontinuation of antiretroviral therapy for an increased viral load.",
"     </li>",
"     <li>",
"      Another series of 48 patients discontinued maintenance MAC therapy, after receiving macrolide-based treatment for at least 12 months and HAART for a minimum of 16 weeks with a median CD4 counts of",
"      <span class=\"nowrap\">",
"       240/microL,",
"      </span>",
"      and were followed prospectively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/55/38777/abstract/54\">",
"       54",
"      </a>",
"      ]. During a median of 77 weeks of follow-up, one patient developed osteomyelitis due to MAC while the other 47 patients remained free of MAC infection, for an incidence of 1.44 cases per 100 person-years.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These studies suggest that MAC therapy can be safely discontinued in patients with immune reconstitution, but the patients should be followed for continued viral load suppression and maintenance of CD4 cell counts. The appropriate duration of MAC therapy and the duration of immune reconstitution before stopping treatment have not been determined. However, United States Public Health Service and IDSA guidelines state that at least 12 months of therapy and six months of immune reconstitution may be reasonable parameters [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/55/38777/abstract/14\">",
"     14",
"    </a>",
"    ]. The",
"    <span class=\"nowrap\">",
"     USPHS/IDSA",
"    </span>",
"    guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus, as well as other IDSA guidelines, can be accessed through the Infectious Diseases Society of America's website [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/55/38777/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?43/39/44658?source=see_link\">",
"       \"Patient information: Preventing opportunistic infections in HIV (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6553746\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mycobacterium avium complex (MAC) refers to infections caused by one of two nontuberculous mycobacterial species: M. avium or M. intracellulare. MAC infection is most commonly seen among AIDS patients with CD4 counts &lt;50",
"      <span class=\"nowrap\">",
"       cells/mm3",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      These organisms are ubiquitous in the environment, including water and soil. Infection probably occurs most commonly through inhalation. There is no need for isolation of hospitalized patients with MAC infection since person-to-person transmission does not appear to be common. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The two principal forms of MAC infection in HIV are disseminated and localized disease. The most common symptoms of disseminated MAC include fever, night sweats, abdominal pain, diarrhea, and weight loss. Laboratory abnormalities frequently include anemia and elevated alkaline phosphatase and lactate dehydrogenase. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In immunocompetent adults and children, focal lymphadenitis is a common presentation of nontuberculous mycobacterial disease. Focal disease may occur in patients with immune reconstitution on antiretroviral therapy (ART). The symptoms of localized disease have included fever, leukocytosis, and focal inflammation in a lymph node (cervical, intraabdominal, mediastinal). (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Localized disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis is confirmed by the isolation of MAC from the blood in patients with disseminated disease or by isolation of the organism from a lymph node in localized disease. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Disseminated infection'",
"      </a>",
"      above.) Species identification using DNA probes distinguishes MAC from Mycobacterium tuberculosis.",
"     </li>",
"     <li>",
"      Daily",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/57/10138?source=see_link\">",
"       clarithromycin",
"      </a>",
"      (500 mg orally) and once-weekly",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/43/33456?source=see_link\">",
"       azithromycin",
"      </a>",
"      (1250 mg orally) have each been shown to be effective in reducing the incidence of MAC in patients with CD4 counts &lt;50",
"      <span class=\"nowrap\">",
"       cells/mm3.",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Recommended drug choice'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend prophylaxis against Mycobacterium avium complex infection in HIV-infected patients with a CD4 count &lt;50",
"      <span class=\"nowrap\">",
"       cells/mm3",
"      </span>",
"      (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). While there is no head-to-head comparison of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/43/33456?source=see_link\">",
"       azithromycin",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/57/10138?source=see_link\">",
"       clarithromycin",
"      </a>",
"      , many clinicians favor azithromycin based upon dosing frequency and relative fewer drug interactions compared with clarithromycin. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Timing of the initiation of prophylaxis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Combination drug therapy for established infection is associated with more rapid clearance of mycobacteremia and a lower risk of drug resistance. &nbsp;",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/57/10138?source=see_link\">",
"       Clarithromycin",
"      </a>",
"      (500 mg orally twice daily) plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?12/7/12406?source=see_link\">",
"       ethambutol",
"      </a>",
"      (15",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      PO once daily) is the preferred combination regimen for the treatment of established MAC disease. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      MAC therapy can be safely discontinued three months after attainment of a CD4 cell count of &gt;100",
"      <span class=\"nowrap\">",
"       cells/mm3.",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H6554371\">",
"       'Discontinuation of prophylaxis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If a patient is on antiretroviral therapy (ART) at the time of MAC diagnosis, ART should be continued and optimized if viremia is not suppressed. If a patient is treatment-naive or is not currently taking ART, HIV therapy should begin two weeks after the initiation of MAC therapy to decrease the risk of complications associated with the immune reconstitution inflammatory syndrome (IRIS) and overlapping drug toxicities. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Addition of antiretroviral therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/55/38777/abstract/1\">",
"      Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338:853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/55/38777/abstract/2\">",
"      Karakousis PC, Moore RD, Chaisson RE. Mycobacterium avium complex in patients with HIV infection in the era of highly active antiretroviral therapy. Lancet Infect Dis 2004; 4:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/55/38777/abstract/3\">",
"      Sungkanuparph S, Vibhagool A, Mootsikapun P, et al. Opportunistic infections after the initiation of highly active antiretroviral therapy in advanced AIDS patients in an area with a high prevalence of tuberculosis. AIDS 2003; 17:2129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/55/38777/abstract/4\">",
"      Reed C, von Reyn CF, Chamblee S, et al. Environmental risk factors for infection with Mycobacterium avium complex. Am J Epidemiol 2006; 164:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/55/38777/abstract/5\">",
"      Carbonne A, Lemaitre N, Bochet M, et al. Mycobacterium avium complex common-source or cross-infection in AIDS patients attending the same day-care facility. Infect Control Hosp Epidemiol 1998; 19:784.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/55/38777/abstract/6\">",
"      Swanson DS, Pan X, Kline MW, et al. Genetic diversity among Mycobacterium avium complex strains recovered from children with and without human immunodeficiency virus infection. J Infect Dis 1998; 178:776.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/55/38777/abstract/7\">",
"      Horsburgh CR Jr, Schoenfelder JR, Gordin FM, et al. Geographic and seasonal variation in Mycobacterium avium bacteremia among North American patients with AIDS. Am J Med Sci 1997; 313:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/55/38777/abstract/8\">",
"      Low N, Pfluger D, Egger M. Disseminated Mycobacterium avium complex disease in the Swiss HIV Cohort Study: increasing incidence, unchanged prognosis. AIDS 1997; 11:1165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/55/38777/abstract/9\">",
"      Fordham von Reyn C, Arbeit RD, Tosteson AN, et al. The international epidemiology of disseminated Mycobacterium avium complex infection in AIDS. International MAC Study Group. AIDS 1996; 10:1025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/55/38777/abstract/10\">",
"      Naik E, LeBlanc S, Tang J, et al. The complexity of HLA class II (DRB1, DQB1, DM) associations with disseminated Mycobacterium avium complex infection among HIV-1-seropositive whites. J Acquir Immune Defic Syndr 2003; 33:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/55/38777/abstract/11\">",
"      Ohkusu K, Bermudez LE, Nash KA, et al. Differential virulence of Mycobacterium avium strains isolated from HIV-infected patients with disseminated M. avium complex disease. J Infect Dis 2004; 190:1347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/55/38777/abstract/12\">",
"      Wahl SM, Greenwell-Wild T, Peng G, et al. Mycobacterium avium complex augments macrophage HIV-1 production and increases CCR5 expression. Proc Natl Acad Sci U S A 1998; 95:12574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/55/38777/abstract/13\">",
"      George S, Coffey M, Cinti S, et al. Neutrophils from AIDS patients treated with granulocyte colony-stimulating factor demonstrate enhanced killing of Mycobacterium avium. J Infect Dis 1998; 178:1530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/55/38777/abstract/14\">",
"      Kaplan JE, Benson C, Holmes KH, et al. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep 2009; 58:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/55/38777/abstract/15\">",
"      Chin DP, Hopewell PC, Yajko DM, et al. Mycobacterium avium complex in the respiratory or gastrointestinal tract and the risk of M. avium complex bacteremia in patients with human immunodeficiency virus infection. J Infect Dis 1994; 169:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/55/38777/abstract/16\">",
"      Grinsztejn B, Fandinho FC, Veloso VG, et al. Mycobacteremia in patients with the acquired immunodeficiency syndrome. Arch Intern Med 1997; 157:2359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/55/38777/abstract/17\">",
"      Race EM, Adelson-Mitty J, Kriegel GR, et al. Focal mycobacterial lymphadenitis following initiation of protease-inhibitor therapy in patients with advanced HIV-1 disease. Lancet 1998; 351:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/55/38777/abstract/18\">",
"      Currier JS, Williams PL, Koletar SL, et al. Discontinuation of Mycobacterium avium complex prophylaxis in patients with antiretroviral therapy-induced increases in CD4+ cell count. A randomized, double-blind, placebo-controlled trial. AIDS Clinical Trials Group 362 Study Team. Ann Intern Med 2000; 133:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/55/38777/abstract/19\">",
"      Sepkowitz KA. Effect of HAART on natural history of AIDS-related opportunistic disorders. Lancet 1998; 351:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/55/38777/abstract/20\">",
"      Cunningham CO, Selwyn PA. Mastitis due to Mycobacterium avium complex in an HIV-infected woman taking highly active antiretroviral therapy. AIDS Patient Care STDS 2003; 17:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/55/38777/abstract/21\">",
"      Havlir DV, Haubrich R, Hwang J, et al. Human immunodeficiency virus replication in AIDS patients with Mycobacterium avium complex bacteremia: a case control study. California Collaborative Treatment Group. J Infect Dis 1998; 177:595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/55/38777/abstract/22\">",
"      Kilby JM, Marques MB, Jaye DL, et al. The yield of bone marrow biopsy and culture compared with blood culture in the evaluation of HIV-infected patients for mycobacterial and fungal infections. Am J Med 1998; 104:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/55/38777/abstract/23\">",
"      Hussong J, Peterson LR, Warren JR, Peterson LC. Detecting disseminated Mycobacterium avium complex infections in HIV-positive patients. The usefulness of bone marrow trephine biopsy specimens, aspirate cultures, and blood cultures. Am J Clin Pathol 1998; 110:806.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/55/38777/abstract/24\">",
"      Pantongrag-Brown L, Krebs TL, Daly BD, et al. Frequency of abdominal CT findings in AIDS patients with M. avium complex bacteraemia. Clin Radiol 1998; 53:816.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/55/38777/abstract/25\">",
"      Pierce M, Crampton S, Henry D, et al. A randomized trial of clarithromycin as prophylaxis against disseminated Mycobacterium avium complex infection in patients with advanced acquired immunodeficiency syndrome. N Engl J Med 1996; 335:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/55/38777/abstract/26\">",
"      Oldfield EC 3rd, Fessel WJ, Dunne MW, et al. Once weekly azithromycin therapy for prevention of Mycobacterium avium complex infection in patients with AIDS: a randomized, double-blind, placebo-controlled multicenter trial. Clin Infect Dis 1998; 26:611.",
"     </a>",
"    </li>",
"    <li>",
"     file://aidsinfo.nih.gov/contentfiles/Adult_OI_041009.pdf.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/55/38777/abstract/28\">",
"      Ioannidis J, Wilkinson D. HIV: prevention of opportunistic infections. Clin Evid 2003; :809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/55/38777/abstract/29\">",
"      Havlir DV, Dub&eacute; MP, Sattler FR, et al. Prophylaxis against disseminated Mycobacterium avium complex with weekly azithromycin, daily rifabutin, or both. California Collaborative Treatment Group. N Engl J Med 1996; 335:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/55/38777/abstract/30\">",
"      Dunne MW, Bozzette S, McCutchan JA, et al. Efficacy of azithromycin in prevention of Pneumocystis carinii pneumonia: a randomised trial. California Collaborative Treatment Group. Lancet 1999; 354:891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/55/38777/abstract/31\">",
"      Benson CA, Williams PL, Cohn DL, et al. Clarithromycin or rifabutin alone or in combination for primary prophylaxis of Mycobacterium avium complex disease in patients with AIDS: A randomized, double-blind, placebo-controlled trial. The AIDS Clinical Trials Group 196/Terry Beirn Community Programs for Clinical Research on AIDS 009 Protocol Team. J Infect Dis 2000; 181:1289.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.idsociety.org/Content.aspx?id=9088 (Accessed on December 12, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/55/38777/abstract/33\">",
"      Jacobson MA, French M. Altered natural history of AIDS-related opportunistic infections in the era of potent combination antiretroviral therapy. AIDS 1998; 12 Suppl A:S157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/55/38777/abstract/34\">",
"      Kovacs JA, Masur H. Prophylaxis against opportunistic infections in patients with human immunodeficiency virus infection. N Engl J Med 2000; 342:1416.",
"     </a>",
"    </li>",
"    <li>",
"     Dworkin M, Hanson D, Jones J, Kaplan J, Adult/Adolescent Spectrum of HIV Disease Project (ASD). The risk for Pneumocystis carinii pneumonia (PCP) and disseminated nontuberculous mycobacteriosis (dMb) after an antiretroviral therapy (ART) associated increase in the CD4+ T-lymphocyte count. In: Proceedings of the Sixth Conference on Retroviruses and Opportunistic Infections, Chicago, January 31-February 4, 1999:198. Abstract.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/55/38777/abstract/36\">",
"      Kirk O, Lundgren JD, Pedersen C, et al. Can chemoprophylaxis against opportunistic infections be discontinued after an increase in CD4 cells induced by highly active antiretroviral therapy? AIDS 1999; 13:1647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/55/38777/abstract/37\">",
"      Yangco BG, Von Bargen JC, Moorman AC, Holmberg SD. Discontinuation of chemoprophylaxis against Pneumocystis carinii pneumonia in patients with HIV infection. HIV Outpatient Study (HOPS) Investigators. Ann Intern Med 2000; 132:201.",
"     </a>",
"    </li>",
"    <li>",
"     Ledergerber B, Mocroft A, Reiss P, et al. It is safe to discontinue secondary prophylaxis for PCP in HIV-infected patients treated with HAART: results from eight prospective European cohorts. In: Proceedings of the Seventh Conference on Retroviruses and Opportunistic Infections, San Francisco, January 30-February 2, 2000:235. Abstract.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/55/38777/abstract/39\">",
"      Lederman MM, Connick E, Landay A, et al. Immunologic responses associated with 12 weeks of combination antiretroviral therapy consisting of zidovudine, lamivudine, and ritonavir: results of AIDS Clinical Trials Group Protocol 315. J Infect Dis 1998; 178:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/55/38777/abstract/40\">",
"      El-Sadr WM, Burman WJ, Grant LB, et al. Discontinuation of prophylaxis for Mycobacterium avium complex disease in HIV-infected patients who have a response to antiretroviral therapy. Terry Beirn Community Programs for Clinical Research on AIDS. N Engl J Med 2000; 342:1085.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/55/38777/abstract/41\">",
"      Chaisson RE, Gallant JE, Keruly JC, Moore RD. Impact of opportunistic disease on survival in patients with HIV infection. AIDS 1998; 12:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/55/38777/abstract/42\">",
"      Benson CA, Williams PL, Currier JS, et al. A prospective, randomized trial examining the efficacy and safety of clarithromycin in combination with ethambutol, rifabutin, or both for the treatment of disseminated Mycobacterium avium complex disease in persons with acquired immunodeficiency syndrome. Clin Infect Dis 2003; 37:1234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/55/38777/abstract/43\">",
"      Ward TT, Rimland D, Kauffman C, et al. Randomized, open-label trial of azithromycin plus ethambutol vs. clarithromycin plus ethambutol as therapy for Mycobacterium avium complex bacteremia in patients with human immunodeficiency virus infection. Veterans Affairs HIV Research Consortium. Clin Infect Dis 1998; 27:1278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/55/38777/abstract/44\">",
"      Dub&eacute; MP, Sattler FR, Torriani FJ, et al. A randomized evaluation of ethambutol for prevention of relapse and drug resistance during treatment of Mycobacterium avium complex bacteremia with clarithromycin-based combination therapy. California Collaborative Treatment Group. J Infect Dis 1997; 176:1225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/55/38777/abstract/45\">",
"      May T, Brel F, Beuscart C, et al. Comparison of combination therapy regimens for treatment of human immunodeficiency virus-infected patients with disseminated bacteremia due to Mycobacterium avium. ANRS Trial 033 Curavium Group. Agence Nationale de Recherche sur le Sida. Clin Infect Dis 1997; 25:621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/55/38777/abstract/46\">",
"      Shafran SD, Singer J, Zarowny DP, et al. A comparison of two regimens for the treatment of Mycobacterium avium complex bacteremia in AIDS: rifabutin, ethambutol, and clarithromycin versus rifampin, ethambutol, clofazimine, and ciprofloxacin. Canadian HIV Trials Network Protocol 010 Study Group. N Engl J Med 1996; 335:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/55/38777/abstract/47\">",
"      Chaisson RE, Keiser P, Pierce M, et al. Clarithromycin and ethambutol with or without clofazimine for the treatment of bacteremic Mycobacterium avium complex disease in patients with HIV infection. AIDS 1997; 11:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/55/38777/abstract/48\">",
"      Hafner R, Bethel J, Power M, et al. Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers. Antimicrob Agents Chemother 1998; 42:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/55/38777/abstract/49\">",
"      Shafran SD, Singer J, Zarowny DP, et al. Determinants of rifabutin-associated uveitis in patients treated with rifabutin, clarithromycin, and ethambutol for Mycobacterium avium complex bacteremia: a multivariate analysis. Canadian HIV Trials Network Protocol 010 Study Group. J Infect Dis 1998; 177:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/55/38777/abstract/50\">",
"      Centers for Disease Control and Prevention (CDC). Updated guidelines for the use of rifabutin or rifampin for the treatment and prevention of tuberculosis among HIV-infected patients taking protease inhibitors or nonnucleoside reverse transcriptase inhibitors. MMWR Morb Mortal Wkly Rep 2000; 49:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/55/38777/abstract/51\">",
"      Hsu O, Hill CJ, Kim M, et al. Decreased plasma efavirenz concentrations in a patient receiving rifabutin. Am J Health Syst Pharm 2010; 67:1611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/55/38777/abstract/52\">",
"      Kirk O, Reiss P, Uberti-Foppa C, et al. Safe interruption of maintenance therapy against previous infection with four common HIV-associated opportunistic pathogens during potent antiretroviral therapy. Ann Intern Med 2002; 137:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/55/38777/abstract/53\">",
"      Shafran SD, Mashinter LD, Phillips P, et al. Successful discontinuation of therapy for disseminated Mycobacterium avium complex infection after effective antiretroviral therapy. Ann Intern Med 2002; 137:734.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/55/38777/abstract/54\">",
"      Aberg JA, Williams PL, Liu T, et al. A study of discontinuing maintenance therapy in human immunodeficiency virus-infected subjects with disseminated Mycobacterium avium complex: AIDS Clinical Trial Group 393 Study Team. J Infect Dis 2003; 187:1046.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3755 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-41.78.124.10-AD1D6AEAC5-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_55_38777=[""].join("\n");
var outline_f37_55_38777=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H6553746\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Transmission",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Risk factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Host genetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Disseminated infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Localized disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Effect on HIV infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      PREVENTION OF MAC DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6974560\">",
"      Clarithromycin versus placebo",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Azithromycin comparative trial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Clarithromycin comparative trial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Recommended drug choice",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Timing of the initiation of prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6554371\">",
"      Discontinuation of prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      MORTALITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      General principles",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      First-line agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Second-line agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Addition of third agent",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Addition of antiretroviral therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Adjunctive therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Monitoring of therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Management of treatment failure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Summary recommendations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Safety of discontinuing MAC therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6553746\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/3755\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/3755|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?26/46/27371\" title=\"table 1\">",
"      Trials of MAC therapy in AIDS",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/33/24089?source=related_link\">",
"      Epidemiology of nontuberculous mycobacterial infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/2/30757?source=related_link\">",
"      Ethambutol: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/35/23098?source=related_link\">",
"      Immune reconstitution inflammatory syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/35/5687?source=related_link\">",
"      Microbiology of nontuberculous mycobacteria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/11/24759?source=related_link\">",
"      Overview of nontuberculous mycobacterial infections in HIV-negative patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?43/39/44658?source=related_link\">",
"      Patient information: Preventing opportunistic infections in HIV (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/42/33450?source=related_link\">",
"      Primary prevention of opportunistic infections in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/24/2441?source=related_link\">",
"      Treatment of nontuberculous mycobacterial infections of the lung in HIV-negative patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/21/19802?source=related_link\">",
"      Treatment of pulmonary tuberculosis in HIV-negative patients",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_55_38778="H pylori gastritis Light";
var content_f37_55_38778=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F64354%7EGAST%2F63916&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F64354%7EGAST%2F63916&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1110px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Helicobacter pylori gastritis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 288px; height: 454px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Medium power view of a gastric biopsy obtained at endoscopy shows infiltration of glands with neutrophils (arrow) and increased mononuclear cell infiltration typical of Helicobacter pylori gastritis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Robert Odze, MD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 520px\">",
"   <div class=\"ttl\">",
"    Normal gastric antrum",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 520px; height: 223px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Left panel: Normal surface (SE) and foveolar epithelium (FE) and glands (G). Right panel: Higher power view of the glands shows mucous cells (M) and gastrin-secreting endocrine cells (arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Robert Odze, MD",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 474px\">",
"   <div class=\"ttl\">",
"    Helicobacter pylori adherence on gastric surface cells",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 454px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    High power view of surface and foveolar epithelium shows numerous",
"    <em>",
"     Helicobacter pylori",
"    </em>",
"    organisms lining the surface of the cells (arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Robert Odze, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_55_38778=[""].join("\n");
var outline_f37_55_38778=null;
var title_f37_55_38779="Ginkgo quality criteria";
var content_f37_55_38779=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F78899&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F78899&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Examples of Ginkgo biloba brands meeting specified quality criteria*",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Product name (manufacturer or distributor)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Target Up &amp; Up Ginkgo Biloba, 120 mg/capsule (Target Corporation)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ginkgoba&reg;, 40 mg/tablet (Alan James Group)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Finest Natural Ginkgo Biloba, 120 mg/capsule (Walgreen Corporation)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        <p>",
"         Examples of products passing testing. Full report available at www.consumerlabs.com.",
"        </p>",
"        <p>",
"         *To pass testing, products had to meet all of the following criteria:",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1. Product label states a recommended daily dosage considered to provide a clinically appropriate amount of Ginkgo biloba leaf extract (ie, 120mg per day in divided doses) and standardized to include 22 to 27 percent total flavonol glycosides and 5 to 7 percent total terpenelactones.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2. Products must contain 100 to 150 percent of the claimed amounts of total flavonol glycosides and total terpene lactones.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3. Minimum amounts of individual flavonol glycosides must be present as follows: quercetin (&ge;9.5 percent), kaempferol (&ge;10.5 percent), and isorhamnetin (&ge;2.0 percent).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4. Minimum amounts of individual terpene lactones must be present as follows: ginkgolides A, B, and C (total &ge;2.8 percent) and bilobalide (&ge;2.6 percent).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5. USP parameters for disintegration of vitamin supplements.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        6. Contain &le;2.0 mcg of lead in a daily recommended serving.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_55_38779=[""].join("\n");
var outline_f37_55_38779=null;
var title_f37_55_38780="Theophylline guidelines";
var content_f37_55_38780=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F53731&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F53731&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Maintenance dosage guidelines for theophylline in children older than six months and adults who have no risk factors for decreased theophylline clearance*",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Variable",
"       </td>",
"       <td class=\"subtitle1\">",
"        Weight-adjusted and maximal dose",
"       </td>",
"       <td class=\"subtitle1\">",
"        Comments",
"       </td>",
"       <td class=\"subtitle1\">",
"        Adjustment to dose",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Initial dose",
"       </td>",
"       <td>",
"        ~10 mg/kg of body weight/day; maximum, 300 mg/day",
"       </td>",
"       <td>",
"        If initial dose is tolerated, increase the dose no sooner than 3 days later to the first dose increase.",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        First dose increase",
"       </td>",
"       <td>",
"        ~13 mg/kg/day; maximum 450 mg/day",
"       </td>",
"       <td>",
"        If the first dose increase is tolerated, increase the dose no sooner than 3 days later to the second dose increase.",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Second dose increase",
"       </td>",
"       <td>",
"        ~16 mg/kg/day; maximum 600 mg/day",
"       </td>",
"       <td>",
"        Measure the peak serum concentration after at least 3 days at the highest tolerated dose.&bull;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Serum theophylline concentration (&micro;g/mL)",
"       </td>",
"       <td colspan=\"3\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &lt;10",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Increase approximately 25 percent.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        10 to 15",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Maintain dose if tolerated.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        15.1 to 19.9",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Consider a reduction of approximately 10 percent.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        20 to 25",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Withhold next dose, then resume treatment with next lower dose level.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &gt;25",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Withhold next 2 doses, then resume treatment with initial dose or lower dose.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * For infants 6 weeks to 6 months of age, the initial daily dose is calculated according to the following regression equation: dose (in milligrams per kilogram per day) = (0.2) (age in weeks) + 5.0. Subsequent increases in the dose in this age group should be based on peak serum concentrations measured no sooner than three days after the start of therapy.",
"     <br>",
"      &bull; The length of time to the peak serum concentration depends on the rate of absorption, the rate of elimination, and the dosing interval.",
"      <br>",
"       &Delta; This decreases the likelihood of side effects due to fluctuations in the absorption or elimination rate that may result in serum concentrations above 20 &micro;g per milliliter and is especially important for patients who require doses higher than those used in the second dose increase.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Weinberger, M, Hendeles, L, N Engl J Med 1996; 334:1380.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_55_38780=[""].join("\n");
var outline_f37_55_38780=null;
var title_f37_55_38781="Titratable acid excretion";
var content_f37_55_38781=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F80603&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F80603&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 583px\">",
"   <div class=\"ttl\">",
"    Titratable acidity",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 563px; height: 234px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Formation of titratable acidity, which is primarily due to buffering of filtered HPO4(2-) and, to a lesser degree, other buffers such as creatinine. Note that a new HCO3- ion is returned to the peritubular capillary for every H+ ion that is secreted. H+ secretion occurs primarily by Na+-H+ exchange in the proximal tubule and by an active H+-ATPase pump in the collecting tubules.",
"    <div class=\"footnotes\">",
"     CA: carbonic anhydrase.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_55_38781=[""].join("\n");
var outline_f37_55_38781=null;
var title_f37_55_38782="Persons surviving after AIDS diagnosis";
var content_f37_55_38782=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F74307&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F74307&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 530px\">",
"   <div class=\"ttl\">",
"    Proportions of persons surviving, by months after AIDS diagnosis, during 1998-2005 and by age group - United States and dependent areas",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 510px; height: 346px; background-image: url(data:image/gif;base64,R0lGODlh/gFaAfcAAP///wAAAAAz/2YzZgCZZgAzmf+ZM/8AAO7u7oiIiCIiIkRERJmZmXd3dzMzM0CzjMDm2REREbu7u1VVVYDMs93d3f/mzf+zZoCZzMzMzMDN5kBms//AwP/Mmf9AQGZmZv+AgIxmjLOZs9nN2YCZ/6qqqsDN/0Bm/xBA/1Bz/9DZ/5Cm/+zm7HBAcKCAoPDz/+PZ46Cz//9gYPbz9mCA/zBZ/+Dm//8QENDA0LDA/6mNqSBN/8azxuDm86Cz2f8wMFBzuYNZg//g4LymvP/w8JZzlhBAnzBZrHlNef+5c3CN//+sWf/58/+wsP/Tpv+goP+QkP/Zs//fwJCm0//Q0P/s2SBNpv+mTf/GjbDA3/9QUP9wcP+fQGCAv/Dz+f/z5tDZ7HCNxv8gIGC/oKDZxv+/gPD59pDTvCCmeTCsgwB/ckBAQFC5ln+ZTBCfcABMjD+ZWXDGqdDs4+Dz7LDf0C98Ul9fP78mGRkz2H9MM7+ZP8DAwE9pRo9CLICzv+8JBm+ZTy9Ghb92aZ85Jr81KaDMzO8DCdDMw7/TszJfxUOZg++sbG9fbB+FWYCMc1+ZUr+zc69/cODW4zCmhZ9yWd8TDDBznxMz4r/GmW9WOY+ZuZ+zeR95Zi+ZXK+gj68PL9+zbK9AMJ9pVr+/jB+ZX4CfWT8mcs+FRu8pFp9ZRu9JRsDGue+ZlrCwz99zbDCZjN+zrVJGZo9TPL/Mps+ZPICJvF8fX3+cg6+ZQt+STD9GkzCmdr9mWZ+ZRl9ZckliUj9yTM+PaT+sgFCMrECApiZMn5C5yQ85kiBmmTlfZgAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAAD+AVoBAAj/AAEIHEiwoMGDCBMqXMiwocOHECNKnEixosWLGDNq3Mixo8ePIEOKHEmypMmTKFOqXMmypcuXMGPKnEmzps2bOHPq3Mmzp8+fQIMKHUq0qNGjSJMqXcq0qdOnUKNKnUq1qtWrWLNq3cq1q9evYMOKHUu2rNmzaNOqXcu2rdu3cOPKnUu3rt27ePPq3cu3r9+/gAMLHky4sOHDKxssQLggQIDFAhs/Rky5MtMKjiEXTKAAAQIFCQBw9gzasunTRBNoJjghtOgJAFoLTAAbte3bOlUfVMBAIAMHAHj7Bo67uPGYug0KB/A7eG/mxAGscUy9uvXr2LNr3869u/fv4MOL/x9Pvrz58+jTq1/Pvv32oskLygbQAPb8+gwDHN/PVn9qzRIEIIFonX0W2mgG5tcBfwye5V9QmFEXWoADAiCZZhcyVEUAqARjQYMghvUgWQEcYAsji3wY4opajThWiZ8UEMgpF6jI4o1TuShWAHxUYkoBx1BiwBVOMIHjkU7pKCIBdhiiSwEF+GLAlEk4UQWSWB6lJFgBEEDAHT/UAmUguUw5JRcXYNFBFBZYcGWWcOq05VcBJFLMLwf80IoRBRihiRNJcGHmoAYk0YETbX4R56IxzelVAALgwYkdeUqyAZQb9ADAF1J00MEFoBI66BIXGNqBFBYoyuiqIjnaFaR4JP9DwCAH3EAFBnwW0IWmBVXhRAdJhCoqoVek2UGqrCaLkatcwRqLl7Te8EQPQEBZABA+eLEQE21G4Smogg57QRmnvqnsufk5GOkAiniZyQEHaEGEBtVau8EUYEhUhQUdlHHBsAYsYSib6BZMELNbQXrJAC5Q4GUdd9TaBAA9YHCEtX1ugIEGFHHrBBYXhEvsBYdaYKTBqyLcogACDDAAC3S44SUwEXsghEA9+NCFFRgXcEQXPuRbkQXeXnDFsGiSiyzKSKqcFaQChMAwAGaM4SUBdfTxhww3D5RzFxf3rHEWvFZURadJLAEwqWuazDSITmMFNQwujyDQHGPI7CUfoYD/QIRBXmiAARC5WmsFEFNwjNEX/IIsMqGltv12cXFfBbUNOgzQwgwDmUFGGlc3kocrXR/UQxZhXCr2xhtx623aAKOJBaKTW1a5VQGcIIAJMwQxQBAGzREHGlfbIQgHDIExxc4YG4G40Bwx/usFaotabLm1E3Z7VbkLkAMAMLQw9UFkPHB1HamwUrpCX/NsrfOsg3Q2sNVDrrSq2e+1PVUBKCEACQIZgctckBC86Y1JkXjC3xqiPML17AhA2FjZPEI0xw2LbYjCX/7ksr8ckUAANBgIDwbIOYR4DnRX48MtVmGGhygPbD2D0hE0ljjocYRb/QrZ2ozlpg22pYNSCYAJ/wRwAoKM8HclTIgchnc1L7nhAQ8YAwWmOAYoPmCKZ4BAQTQwhdQV7oERJNtHXAcsHV6QZFIwlw9f5CAbsKwgIxBfC+zGkDmQYQwobKIe9eiGMWgRcBrIAga6sIEv2isMPlAcSCzQKX89zkwCw94aH+UgAKBAACooCAx8NwARQEQIsBAEIfqQh1L2gRC88AQVieclNJyhhQvhohdjCEEMJFJbISHap45mPZJlcJKWq2QKBLACg8ygCC4LAgwkQgUQaOEG8IrmD7bwhEPk7WppkCIFyACBbnrTIKcbnPtiaIUNdMGWGsBlRzwGMl6KCoNLA2ZTgBgV/axAAClAyBDE1//JilABCjIQQzThdQNViKIOe0woNqGoTW4awwcY2EDYYpixc2bBhhxhZBkBFjAeqlGeQ6EnVPSjAgGgICEskNoAkICDixChCSDwwEAP8Ic7yMIRFGCDFaGYR4VezQ1sOMMcAKABLkZ0omBEJ0jIGKxHmqlY5EIVSH8i0qf455KZTAgP+BkCOmLknwEd6A20AAUqIMSbZ5giFFmJzThw05sQKIQfhmGJN9j1rndFBjH8UAi4+hWuac0iXGG5EI36y50jU1M8p0qTqiZJIDQQgBIWMgMRuIxhLOCIEJ4Q1miOFQQcWOBC5HAGNvj0tKhNLWp3ylopclMg++pAOwEWuTT/MhYmjp2nQHIggB00hAUuuKwLltmRfz5zpj+QARSQtxAz0CGnrI2udHc6CTVY97rYte4rKFDFnao2oWlgwxThighMQAIU/xrW9Qh2W5TklikPuqQJHALcy3YVJFTg7A9mmiflMjckYBAkEFRHThpqYIJU+ytaKfAAtqZ2F3AARBt6oQda9HJ2bmsvSN67lAdFNoQPqW8yeTASDkBBCwKdqRi0AFrRgqQHgkvdOMUWwUQ6BAJkoEAcpHtAhXYCDhFuQxtwoYciyw5RJ9PwsiopkJIK4AURAS4/W6CDzI6ECBwAgQz2q2IPgKAJ6wtJIAdH4J4ZwZwbw+hDzNDNKerU/8GpJQWQrSjeKdrZzoJVsJ737FfCJovDShmR7gAokRkMAQn2JfFJTCwDmfLXA1tYrkkCN4WjUrQA5cRA4hAskW4+V608/a6oR+1TNFyRAt+EE6CTMqIYmBTKFMEBMl3WguGqJL9b8AA0VcziJpjVJDDGgIwvvYEaK5IjcvDmLEaxiVII+dnPfgSQ4SCM6Vrb2j0ltZeguM0/2mbVSHHRDv53ERYc+rJIEIGVVSKELGuByzP1gAxajJIxE/LSZw6DBJdqgY+ZUVTjOlWGKSKH5+74AdkW9RNZW+c7o/qvaXW4xMfbTT+z0SwucjUKYH2REbiAn78bwrpZwoEn5HrXYv+F9HJdTJLAQVSil66ljRf5uvoB3Jc9FAmbc9xgbfs8oQzFojflkDAmE6QGkuWIrC8b8pG3BMtadvSj5/0EDvzaJGAQHCENCaVMBy0k0vuUzQmFJpIda+AeSbZfc+zwg7d24hJ3u8/TcO26szYOcH+rgiX+Wo+AW0sGGSImOzIDHszaZUjQAXFl0u6o89ez8v7y1VuugZfP2F4R3JgG1KwRMh6Wo0OKnMA/2hM2QyDiOl3rz1fvczSQoSN/N4qSIlsDkBS+CCCvNQ6SOJN2QyGmun58f1eOEjC8nOti24DGMJCFY2uEcd4CWXpBTypDIcpGR+Gz9v8Kd+hOV5t2ZgP/K13/R9P/le0T7y4UY18UJb3gkoQOCQ4+zvQQDGHxOKGCiU/O3xWDNiUuJ2zKd3kFFgabJj+69ClGA3oGACqe0iZ4QQE9xnpXw35EsSW8tTslAQM6wEmI5wI8wHs5gWUABW/S5F8uETiVJ4AEKEMGxmkd0Sa/4i9jBzlml3NvYQZngHBXM10NJ3F5BgEWGFIJEVkbdxIsYHgg9zs64FU9wWgmCC+Q9gST5xIBNkiFFHMvSBLc0ikgU4NmgibWh4PaY3QG8QJIVwMcdxIjIAIe6DIhIAJOyBNQh2JTR3wxEYADdmmYtgH61nwl4XkLyFGgoiZsgn16MYRC4Sg2cEkg/7YSM4ADOoBo9SeHQVGHKZZy89YEoSUTAbh1fFhsmnZgJQF9OYRYSAMq5CJwiOgWihgUruJkj9gSSegClGhflniJWbZlwpcnXrZcVegSRSWASNUz5fSH6RSIbeIpwQKG4iJ616dBF1cWzOJqIDQTtXiLcCgCuzcUjZdrUThQYqByHBBmLgFjEDVgyIcpBsZ5IbEv/PIt1MOAkCR6qCKNcmOGCWGNsygT2ch0TMgDTqeLMNVoKIdcLFZ1NTGMloZvaHZLK8E4CRgs08dRZfeApGdV+riPLNOPNMECkviGmlMEQzCHRcEBBRl8/HUDXkaFNvGJG9CC7DiKMIgS3JKA4P/CUcWCYUnWYRvJkUS0hjcxA22oUvWnAzgwkEWBZU8QU+F4AF4GZjmRdZWmfHw4Q/pGijHBOF44iGSXJuwFeBgHETlwSTWQVT0BA0NgiwCJBEWQi0xBBTClkgNFjuZIEzC5jjOEAZo3E/MDO9ZjKLa1iD+pECpwSSjwPUERiSJglJcVBCCIf0ohBHN5kNIEaaD1Xzhhb1mohX7Il8xXVDVJEn+JilMSSWzSkzjxikBxO2jIMkoglEChlmwJkHGYlE7ReAbZix7gZZmpE5wpkxR1ZqI4ilpJEhX0bzaoJtfXii3BmlRFEf4jAGeJFETZmEs4knIogkuBkiAAjr3Ikiz/Bow5oYKCxJepo3zrSEvFmUjOd0O6NI/0aCagUp+ryIqquRHQ6RMdVJYsE39JAZI64JiI95Ym2RRMGXWZuJIekJDl+BMwtoJkVmZ8WE7L554e0YXMCCrOSI+koiZStWRjWREvMEy9NV9OAQM84AIi+TsuUJJW0W5NuZvCN46b2IlBoYIQFVEwx4ddV5zNN5oZcZNt0m+eooAdmjRt45wKsZ89IVL+iU82IBUjsJYtCpkwihX693taQJf89QO+aXVGkXXnOWDFGEPEyZdBihLLOFsMWJ9wGqcX4KQ8UVUvMJ0oQAKy+RRtWATamEw6wAOSeRUckGXA14s2+mWaWRRF/wVR6bmefRhBB2gSYdeM8zkodLoTuaUCumNSAEoV1+mnADkAIRCog4oVWJaSllmXDnqXQwFj56meFYpmmiekGVqkuJqrFpCpctIROTBuvRUDWxGqf0qqphoW+vedHvCU8AKmW/CbS0GVZAapPqN8+haax3kSvGoRGVIQkkEdABAg1LEaCLFqMQCsO7ACe2oVxDqqpSqoYyGjziR1j9egIECeS1FUlfaoPvpAylecxvmeFbGtFIEgpYEQHwAbAQIRf3euLJOnU/oVoZqdxgqvZeGd4Cl84gkCmclySFFU58mjndmv/vqZ2KpOC0GwEzEftIEQmFEB4Ro37OewHYmiYf8Bktjprsd6FvJKo8IHpjfqsUuhgo0KmgPWoyRbAMqXeRg6ECorEcvRHAcxAR8gEOIaAA4AsylbEjnQqdQZA+vaFTgbAhT7rqdKFj3bm73oi8/KiVpRVILDl8p3phRVTk8bEVEbHQQRIFo7EAjgALWxB+9hEipAA5dkUjSAlmUxtmW7s21RqByrtrwZpouKFToqt0hbALzqGZwLEfdRG95atQYRHwkBnS+wAsDaWysQsWjBuO7KjWerFhi7rOFpr/jqFVmXqQ1gHREgugxhsBMiIFYbAX37AaFRAQ7gGk3KEiZguCyDT2DLFq4LkJAph0rJFgnaaAs6Uxt7u8HEErv/ex3KuxDdSiECcbC+EQGOAbrL2xIvEANeC71hu7g4kLM6W5Lc+RZpu70pR7lB1BIN4ACekQEBwAARoLfPGRM2sAJI97wpEL1vQZRrSaC0Vqr4exf7u7a9+axV56qw2BIOQByYEcAIzBJ3CwAL3MAskwKrOxcs0IYuQMGaY8EjkL9ykbbMSlC9ybGcGIy9yhIT8BiKEQAJEMKNchMp/LzUSQKKKxcwUL9F0KIzrAMXrBdYZqi9uarIZa+KiqMzkakVoL6OoQDIO74JnBMLbKIsswM0kAPz6xZPLAJRPKpTbL1+0W4wBXxa/KVcXKgm7BIIkAANkAAI0Fg98b7O+7wn/7ACTWwXcTzHdBwCLiCHsYsXV/x7wEevwrfBiurBGrGtnFvIXxwUJqAEKoy4McC6evHCIhDDdPw7b8kDBwoYhdqUGTu5mJmZnuwQmZoBClAdDTDKQ2EDMZACh8syNaAEiukXLzwEA0qxK0XD1wsYqRq5mqyxO6yoQluuLfGtjhHMMnHCFKECJBC/REQCNvsXRMkDjVmscPiWODDLg3HFhpprXtp/kdfBB5GpC0DGnSvMSfECOWDKSoxPjFwYcezKdIwEpWrHqIHH1ry2zgpaVJCpJVAgnmHITkHMNJC6JsXCjRwYEtzOrxwEcSjLNkwZkHuoj6e71gHORywVxGzMSv+MAiBdGQlNtq8cAvAsz5XhnQbp0sAM0FShAitA089r0wdtGessxzI8w5Mcz5SzEqIcyqIczlth1Ej9sDeNGs3cmFIM1dzo04GxnwgQAA0QvtQB07j1FVp9zB+91Lfx1SHgzmIdzymdiCpx1mn90kTt1kcN10od0qgBA204oGFNqrE8AtM8F05a1aGs0WXx1jXd1fxB14lt0iJAyXWRqbRRAjchzjZB2Ult2Q3ywuxcBE8t1ij9QwA8xgmQAZLNFqTN1XK9IkRZvzFs178Th3JI1kXXEhLwAb9MxH/tFrUd1+mMI4Y9BI252i3A0yJQkpXMPy9RAZyB1scdF8l9zm7/HCe5LQIDytvR/ZbUjTstUQLfqgCgjdV6odUe3Vs0sALLDSeo3cp1/cozbN4jUN1ECL4BEAETUCHbjRc2MNDmTETKrMqr0txODc325dsjUMPt1xIMQMihTRgmcNTxbdPo/MZw4uC7rd+9rQMiIMv+HdMpAdn/7N6GceDlXNDyTd+Tc9+ITeLR7dvx3NgqYdZordbfXOCFoQIxQAOnjMw0EAOEbTATvtmqDeEV/JZjzeMbttc/7tcubhsbngLxreBKPkkvXL8DutoVrOP93SpULRBWPdvF8QImQAJcLuMnoARfDlKGzc5jTuJwKMmbPeF5zcst8dkZHiIwfgJwzTJz/17nt2XY9fvcUF7mJl6SFN4QQg0asi3kDFLoh06d813ft0WUbYjfZB7hkzzW+Merw13cZuwSov0WNvDmcV7QNZACH65kB/HCoR7Do454IbCt2P3LbP0SrT4Xbg7nXb4DJ0ACObDkti4QuO7cY66NFr3e7a3iBbPhRi7jCk7jzf4Qhu3SAk7gWf42RK4Ehi7jO0DrOcDg3W4QmXrhV83m+fPqcH7kiK4E9A3ijAXG1V4Tw44YJhAD5r7pyE4CMeDp+x7oARDvmC5P9J7tMj7rys7s+QPGxNvi1t7uAKACOVDOXU6dtG4C7F47Qr3WDd/uAT/w2n4CNIDOI48uJR/k4/+u8Qrh5iug8hGv7hSfJZsb2SdP8whh8zgv67R+8CkDyD4/80A/EUJ/7uie7PneNK891Eq/9BgR8B6v7UTU8sseIjGv3VVv9RzB8XCe4GsM9SJvHD1PGv0u7GKfEq9+8yfw8URU9AhfGGtfAQpArqz+9i9hAh2fAmZvUiyv7HffF1/P92fs9zJh8+Vs7w9b+Dlw+J099WN86RnP+DUR91mv7ShwAnav72qx9iXA8G6v+T+hAm/++FpPRGi/8yQS6MTbGMT786iPxhtezoPfW5JvAqLfIiA8AQSsAL1r+7fvE24eAyRAA06v7TUw5+hM+ejNEg7QAAxAxAFs/MdPFKr/TwK63/qu7/2T//us1hITsPcBUALZH/YF4R7u/x3bLxBu3vHmDvnP+/xKYPBpr5EsARAlAgRQAMDBBwAJFS5k2NDhQ4gNA0RcOJHiRYwZNTK0uNHjR5AhRY4kWdKkxhcmcpBQcqKGAJgxZaI4cYIEiRwmbJzk+bFjT40lGlSo0CAD0JE/IypF2pSjU6hRpU6lWtKEiZspTqCQ2VUATZs4dVYtyZTsWZ8ZzaIluZbtW7hx5VK0YSIGy5pevdakcfPqzrkVAw+WqJawSLeHFS9mDFSF3Zs1ueqVyfdmThNsEzeuulmhZ86fQ48mXZpkSqwkaOSl3LVmipskrmYGCrrx/4KBCxpKGJg7Ie4Aui/ath26uGnkyZUnRL0issvWXmu8jr1itgqNx5si4I5gYwIF3BUkYMibIXjx5CkSX164/Xv48R3Whay65svoXlHApu1Qe88MFOgtgAY0mkC9BCYoT6kDE0pwOMOqqiACCRT6oDf1QPpPPg47LG22u7Kq6YQd9KpBiRgAS2jDk4DrrcCMFGAgIQYcWHAgByoAQEYabVwvQqcQmBGACwOoMCEHjmIgAO809PBJKKN0SIUYaMAvph1SsI5FkxZQoILuNuIRgBofQsABBccsE4A9BnSTvaYymCCAIVc8cqEEfHRSSj77fPKFlU7oisuSSggvTAPVa/9AwYcS0K1BABaFEKO1CLD0UkwzhaChPB3I8LM7yRzoqJAI9fNUVAdTYYUUdjB1pAbchBEj9BAYDwDeKvyAvAo8BaDWW3+k9KFMi8V004Vwq5OjUGmMoMm0UpV22uVeFSnWAWfFCDjhciUzgoEYBYDbYcvtqdNP7fSv2eyodfdd4+TqjjvF4ERKTjorOlKCBXRM4NlS4RV44MCsFQk8gtKdy97thixyIAAqAE4Bdtsl+GKMO4srATeXXRhI+AzOeGSSBYNrgSQRyMAB4QZj+D2RS5YZ45g9OshCPQsGGeaZe/bZ4rcunGDRABAi7OX2av55aVSV1sjW3sI7DOlqmbb/+mqnn06ggQSgdXnnpK8W++esKWpyXq91NjfksduWuWyIECAQ2xenBrtqt/OmmS25G6B7IG0/XptnvQsXGO64E0K73ruVQ9xwyBmHKwGjIw1cLqodj3zzVB83swEHuvsgZ8Enjc9zzlPX7C2B3mxZbdN5mvDOhxVGYM4AIliWN4/dU/13D1FnqPUBFSD168FLKvLOJEVNu9ejYlVoQt2FBf760+FCgHJE7U7eJCM5Jb28ggCwFbzen8J+/bDhqqAEzjI3YH7667ffgnUXWjKA4x36QMdxFWhMEBEe+wxYlo0xqTHys18D6Yc/ibCLAc/izUDulABSNUA4A3xIAQ/4/8E9vWVCYKKX92LHk/BF0CELgN9v3FQ5/4BQhguMy98IZELr9SSF/PIXwBbSK4UlhIMxnGERj1ZDWeFwKUB52EQkNhCK7aZjCxmi74x4Rbh4kCGLUyIBOaRFLIYRAGBUCMKCdcTvaU6Ma9TY5KaIxhO2j41zhAoZx5Wylb2udDkkHB39WJu43Cwho+tiB7/4R0SiMC5CIxoM97hE+dgxkeuzI9SgmDbMNS45kpzk9SS5Pa5hMpNp3GQnTRlCuEigBP1DXhzxdkpYknIqAerNAkSZRU0ih5Ox3JwdcaMAB4DrcnHJXCl5eUxDnsxHthofMXNpml0is3B2NFR3DnLL1f/J8iO3G0j1xjUgdtVuIbzjozSRaUcb4qiV5RwJ9CJlkQUEUSHNW1KTqJc+k5nTnOh8UwCamU1XmkQC5YsnrZY5niqqT5/S/CTasImWzBVAohOlaEU18JD/uXAg8twfqRYgQHyKZqEMlYsZ5YnLNFZUpRS9KKdYKaoMVDCFzkKABoUY0hWNlKRuHBBOIfpMkLCwgxUDlYsG4kiF6jSWvsQjywpJxJMA8Yc5+pUPFcLDqnotoflUKiztKEgi/fMtxQSJTAfCAARMjF1PJEiztirSrnp1kQEY2pyQ6kxtliaacV1aJQV0yadasY987eQnt9Y1yQXUmIQtbFzeFz+gkmb/r4ydmR059lC8KlaXlG2s+yJAQsz+NK+S5ewk+ZmtwCZ1sKWl42nrBkd2qpG1fmxo99YJyezNlrba29pLb+vFSOp2t3wD11kZQ1ZoCre1b+HYBD4QAbFmNraLVa4YwRgrHV0otKLVLEjE+c3eEJWcV80XbqsbxusyqabqTex0Q0JPBRY0IvecXgS8Cdzzovct6bwhbM17Lh/J10wIHdL53prT/OqXLfwdJkTIxRAG/NWWuBqQHqEa2wNkWMMb5jAHGtJRjQYgiB/d0ZBIfOAxJljBfHPodw51xkHyKgLkMQ/QMMxhHGvYww6ZoNeWFNPw2rTEkdqgTyerYmodOVEO/xJXQxYwoxpHNsVOmam6kvVCoxbtv0gGoZJjNKQ1NSQD6pEpVd3L1ZJg9V8I6FUPsTlEFHuZy6eS80XU1MwKIPVMjGpTPyE2Wo2wNYpphSJRb8qQOM+5iHWmCKQkVR4LOyjSqsUv2xQtQ0ZHBFg0Dh96FrKriPnqzHC19KU/mOmIPNhbRi3IBMMFaFR319Spi/VYpRyvWR+w1gAdNWlzbcBdc7fXown2r19Z2VtD1tiUJFuyabhs7BWbLMjVK7Sj3WxA49rav5N2G2Xt622rrttUoTa4w825cU+l3B8Zr1HZ5W7yGvnc4sb2tz1C33GdNN8NwXel5w25dEtl3U8j8P9v9C1gxRV8y//WW8CjkrkBRFziE6f4CBhyYhNjaIUaD+CQF85wtzm8jo2jeMknbnGFCHmIP5ZpqH6scnmDHOD1HnZGsuzIKkfw5h+XudhETmVna4RHbc4qQ4i+ZirGvOcNpznPScIjQre1IVGPYtJrvvS3Nd3fcsR6237elIEru+te13oyczv2sX0dKWF/Ntp9XvYLr9btfYW7YLk+d7r7jO3HxTvW6k7pY/dd739H890Fj+zBZ1vsh++Z2gGp+LYzHvGNDzpF9A12ySee8pC/CMcuB294ozLzJHO8DitPkQrMSVsI33dbRj952Dt9JAi4kHpYz3rRv35vmo9tfmT/0p8t1j7Etud47nVPsNIrMo2+jwnwE5L6/kKYf/qbvvGPfzjCk9oknl9Ks3Ju4+sjP/sI5kkQj/6s82837uHHPu9l/5Es64bqFZo/Yti/+83bW9v3b3/+rx55/nuX5DuJvVuMAQxAzpuWAmwvBEyy8Zuys2tAB3S/rQs8CeycBxS5A7xAs4u9CpQtDsRACuwgPytBEzxBFEzBEgxBBXxAFtwp/3tBvtpA15NBxqLBpLDBG3RBHZSrEexBfcJB+wPCrhLCgCFCpTJC60PCY1LCaGHChUq3B7s439CoSQM8KOSlcdu083gx8uDC/8vC5WoPSHmQhShDBUFD/RPD4VqO/ztDNDCzkTcMQzZco3GbQ4V4QzxcAxXsQz/8Q0AMREEcREIsREM8RERMREVcREZsRBN8D0drMgCIxElUFElcv2mzNU3cRF7LxE70RE5MDi70Fi4Ew/cbuU/0tlRURVA8CzKyIymsQm8Br5aZwlMEulVUN+kStlbsRV/8xZGBxVAERnLbRVY8RmRMxowRxlwUOGMkxocbRmXUxR8sxmaMRpSSRmrkRWh0xmrcRlfMxmvERm60xnFExRgMx3PEPHEsR3DsRnRcR3hhRnd8R3XURm+sx3yUx3dZg7jwR7YAyID8R4IcSIM8SISsQ4VcSIZsSId8SIjEHgkAFwqpCiEjE/8JU7+PWBkc6R+OASCkELQj4SYRk4rxcrWShAqOCY6EmMjcMbSyqLBfea04cYBXmx4FuKuoskm6UgiO/L6SmJ2rosgjQcnLO5UZq6qpqIAqJBIZO8qQYIAJ8A6nSogSABeQBAp+8Q5CMogJkwr6Ykr4EQjfMgnQ6Z+k/BequJUnAwCBgMmRUIACmZAMCSad7BKEqIBbmZAGUx4LUoi0jICICYCxrL53yYCOMMyocJQV8qntMxrEFIisdAoSu0qqMLAZYcqjkJvJPAm56R/E/Iyy5IkIk4jOPIlgcYAhmQDnusuyOBLGfLQ6OpLQXJEM0EzzCYDTTJXSFKIWkgrGZIj/MZuK23k+BSgBptzNk7gQqWmAvyqvpsA4GgkO1XQKgfgrhOjNHfnN7RiiBIDLkQgQloGRPCES13w6o3FOg/gr4wG7oiyf7RQVlHHMPtHO46SK4Jye8zyJqUQSXtHNqfgA3ejKemoKmIsYipETqUGKCdKRDIiAErBP7kQK8Bge+hSJeKI9/jGU7NpPkaAlgpBDGOnK2njPPETOBJ2ABT1Mi/hM/HwdfllKMxujN4IK8zDDMQLPoHqh/ESxkJhIhYin2nTRILmvX+lLk6hN81zJqJmKoWm9KNMh2mxR/unRC5WSwKyK/PS0qJhI30pOp6Cc39ANUrQqp+CRt6QwHd2m/6REzArJUpXMmQW4RKCQG16BsQ/wUJJogM/6lS+ZxCtMijvJ0jSdRXhxyYoEywEhD1YLUzcBSTBtCgngSTNbyaqLijFhUqj80b8iM6KECqYMlRdyigi7SQvR07LqSIXAnRldzgFpyU+dyY2KSFqtVVu9VVzNVV3dVV7tVV/9VWANVmEdVmItVmM9VmRNVmVdVs4SCMEkCeCY0MZwVmZlGor0DgQAFzqNm1Fxy9whiSURDpvcVE6ZVQBAzN5QEJ48KpCkmwbAJ2ptrqqYE3KtVrgorgIpkm01k26lVljpr3ENCfZcCJtsoYBdEqlRPSZ7CH+1154Bl2By1p6U1RuSG/8C0VYAKC5/ctYiQZDeeNZ56o0kIZ4IwJ2BUJmJgR+b/ABgWhD7mqmCRZKUjBWEAJeTcjWKnEkFoRtvwh2MtckJsMnQOVfgaB6KFUx6xcjeGE2HRQtwcTW57MlYUZALaQCLLYFsNRKLPQpnRYB49SfLI4h3YpSAtZXwQEzBXFfSuZA81TKZNdiUXBIbMVm5FE6C8NpvlVfy0s1Y0Y2pNYgbGtesvU372h6wXVURQ1uNbFqqABehELG/FZAZuc6tzVjCrFxqRVchwRGjgDAXEcy/BVzy2J8B4cggAhdV+ta3lVn1kFtJS9eFoFlvFUx5xZeltckZ+duAVT2ElVkG2B//B+hcemXK3HlXxh0Mx025npRcbw2PbnVczP1Wzf2VhwFJ3oiADKDW0D1YsSXYlKS+N4pZ0U2IWAmcJQHZd0KIr1UQm91a3B3b8eXd7n1fyukN6CMPoSiuKz1ep0he8pXanqzayk1e1J3dcz3Z6RkIkPxa0J1Y3CCPrOUVWwpYKjSaCxFXwmRdUZEa+dJbqxTb89VZi5WACsoAtp3EntxdAhlc6oEW4r1fKoJO/n0L/4Vfii2QAc7glXSAzD1Zuhmiov3W0L3Kk80AF1HX732+v6Qw/hkQJO6ND2iSBKFJC8GRvO3JHR6VqFvZ+L0hI1bVH54ReiWeJJ5hJKNgM8Y7MHQ11zRuYzd+YziOYzmeYzquYzu+YzzOYz3eYz7uYz/+Y0AOZEEeZEIuZEM+ZEMOCAA7);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: HIV Surveillance Report, Volume 20. Diagnoses of HIV infection and AIDS in the United States and Dependent Areas, 2008. Available at:",
"     <a href=\"file://www.cdc.gov/hiv/surveillance/resources/reports/2008report/index.htm#3\" target=\"_blank\">",
"      www.cdc.gov/hiv/surveillance/resources/reports/2008report/index.htm#3",
"     </a>",
"     .",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_55_38782=[""].join("\n");
var outline_f37_55_38782=null;
var title_f37_55_38783="Ortho Evra PI";
var content_f37_55_38783=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F57796&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F57796&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Ortho Evra",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 336px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Skin patches like this one deliver hormones into the body that help prevent pregnancy.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.orthoevra.com. Copyright &copy; 2006.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_55_38783=[""].join("\n");
var outline_f37_55_38783=null;
